Search

Your search keyword '"Bueno, S"' showing total 524 results
Start Over Author "Bueno, S"
524 results on '"Bueno, S"'

152. Dialética da diferença = Dialectics of difference

Author

Bueno, Sinesio Ferraz

Subjects
educação (filosofia), diferença (filosofia), dialética, teoria crítica, adorno, theodor w. - crítica e interpretação, Education (General), L7-991
Abstract

O presente artigo tem por objetivo problematizar dialeticamente o tema da diferença de acordo com os conceitos da teoria crítica. Em um primeiro momento, o tema da diferença será pensado em sua recepção negativa referida à produção de estereótipos e preconceitos de natureza étnica, racial e de gênero. Em um segundo momento, o tema será tratado em sua recepção positiva, muito comum entre movimentos sociais de esquerda e meios acadêmicos. Em um terceiro momento, ambos os tipos de recepção da diferença serão problematizados a partir do pensamento de Theodor Adorno, em sua Dialética negativa, como possível via de mediação entre a particularidade empírica e a universalidade conceitual

Published
2013

161. [Idiopathic ductopenia in adults as a cause of cryptogenic cirrhosis and complications of portal hypertension]

Author

Rodríguez Martínez D, Conrado M Fernandez Rodriguez, Rodríguez Prada I, Pereira Bueno S, Butrón M, and Colina F

Subjects
Liver Cirrhosis, Male, Bile Ducts, Intrahepatic, Liver, Biopsy, Hypertension, Portal, Humans, Cholestasis, Intrahepatic, Middle Aged
Abstract

We describe a 56 years old male patient with long-term chronic liver disease of unknown etiology presenting with esophageal varices rupture. Prophylaxis of re-bleeding with propranolol and endoscopic sclerotherapy failed to prevent further haemorrhagic events and the placement of a transjugular intrahepatic portosystemic shunt (TIPS) was needed. The portal hemodynamic data revealed sinusoidal portal hypertension and the liver biopsy displayed ductopenic cholestasis. The patient met all criteria of idiopathic ductopenia. Subsequently, the jaundice worsened and the patient required liver transplantation.

162. Tuberculosis trend in Madrid region in native and foreign population (2009-2018),Tendencia de la tuberculosis en la Comunidad de Madrid en población autóctona y extranjera (2009-2018)

Author

Pichiule Castañeda, M., Rodero Garduño, I., Febrel Bordeje, C., Ribeiro Alexandre D Auria Lima, M. C., Rodríguez Baena, E., Córdoba Deorador, E., Sánchez Díaz, J., Gil Montalbán, E., José Francisco Barbas del Buey, Jiménez Bueno, S., Zamora Sarabia, A., Aragón Peña, A., Velasco Rodríguez, M., Martín Martínez, F., García Marín, N., Mata Pariente, N., Rumayor Zarzuelo, M., Pérez Meixeira, A., Miguel Benito, Á, Sanz Ortiz, C., and Ordobás Gavín, M.

171. Division cavalry squadron maintenance techniques

Author

Senters, Michael, Maj and Bueno, Santiago G., III, Capt

Subjects
CAVALRY - Maintenance and Repair, WEAPON SYSTEMS - Maintenance and Repair - United States
Abstract

illus

Published
1999

173. Effectiveness of epicardial atrial pacing using a bipolar steroid-eluting endocardial lead with active fixation in an experimental model.

Author

Bueno, S. C. P., Tamaki, W. T., Silva, M. F. A, Zambolim, C. M, Silva, K. R, Filho, M. Martinelli, Costa, R., and Jatene, F. B.

Subjects
*ENDOCARDIUM, *STEROIDS
Abstract

An abstract of the article "Effectiveness of epicardial atrial pacing using a bipolar steroid-eluting endocardial lead with active fixation in an experimental model" by S. C. P. Bueno and colleagues is presented.

Published
2013
Full Text
View/download PDF

174. Evaluation of spent diatomite incorporation in clay based materials for lightweight bricks processing.

Author

Galán-Arboledas, R.J., Cotes-Palomino, M.T., Bueno, S., and Martínez-García, C.

Subjects
*DIATOMACEOUS earth, *CERAMIC materials, *FIRING (Ceramics), *VEGETABLE oil processing, *THERMAL conductivity measurement, *EQUIPMENT & supplies
Abstract

In this study, diatomaceous earth residues from two industrial processes, refining of vegetable oils and brewing, have been used as raw materials for brick making. The aim has been to substitute part of the clay traditionally used for the manufacturing of bricks, between 3 and 10 wt.%, with the aforementioned residues, so obtaining ceramic pieces at three firing temperatures: 850, 950 and 1050 °C. The studied properties were compared with those of conventional materials (100% clay), and the results show that these alternative raw materials can be considered technological “nutrients” whose addition improves the behaviour of the materials in the drying process. The incorporation of these materials also increases the open porosity of the fired pieces and reduces the bulk density by up to 10%. The increase in porosity is greater in materials that incorporate diatomites from oil filtration, reaching the maximum value (37 vol.%). These results are confirmed from the microstructure observed by SEM. With regard to mechanical properties, increasing the content of both residues generally decreases the bending strength to values exceeding 10 MPa, thus resulting admissible for use in construction. Moreover, the energy release from the residues during the firing stage is greater than the energy demand required for drying, while the thermal conductivity values of the final materials decreases with the amount of residue, which confers thermal insulating properties to the ceramic pieces and thus can reduce the energy consumption of buildings. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

175. Response to 'Haptoglobin in diagnosis of sepsis'.

Author

Chavez-Bueno, S

Subjects
*SEPSIS, *BLOOD proteins, *DIAGNOSIS, DIAGNOSIS of neonatal diseases
Abstract

A letter to the editor is presented in response to the article 'Haptoglobin in diagnosis of sepsis,' which is related to Doctor Phillips contribution to the knowledge of the kinetics and the role of haptoglobin (Hp) in newborns, including 'no conflict of interest,' by the author.

Published
2012
Full Text
View/download PDF

178. Transcriptomic investigation of meat tenderness in two Italian cattle breeds.

Author

Bongiorni, S., Gruber, C. E. M., Bueno, S., Chillemi, G., Ferrè, F., Failla, S., Moioli, B., and Valentini, A.

Subjects
*CATTLE breeds, *GENETIC transcription, *GENE expression, *MEAT quality, *RNA sequencing, *CATTLE
Abstract

Our objectives for this study were to understand the biological basis of meat tenderness and to provide an overview of the gene expression profiles related to meat quality as a tool for selection. Through deep mRNA sequencing, we analyzed gene expression in muscle tissues of two Italian cattle breeds: Maremmana and Chianina. We uncovered several differentially expressed genes that encode for proteins belonging to a family of tripartite motif proteins, which are involved in growth, cell differentiation and apoptosis, such as TRIM45, or play an essential role in regulating skeletal muscle differentiation and the regeneration of adult skeletal muscle, such as TRIM32. Other differentially expressed genes ( SCN2B, SLC9A7 and KCNK3) emphasize the involvement of potassium-sodium pumps in tender meat. By mapping splice junctions in RNA-Seq reads, we found significant differences in gene isoform expression levels. The PRKAG3 gene, which is involved in the regulation of energy metabolism, showed four isoforms that were differentially expressed. This distinct pattern of PRKAG3 gene expression could indicate impaired glycogen storage in skeletal muscle, and consequently, this gene very likely has a role in the tenderization process. Furthermore, with this deep RNA-sequencing, we captured a high number of expressed SNPs, for example, we found 1462 homozygous SNPs showing the alternative allele with a 100% frequency when comparing tender and tough meat. SNPs were then classified into categories by their position and also by their effect on gene coding (174 non-synonymous polymorphisms) based on the available UMD_3.1 annotations. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

179. Levenberg-Marquardt application to two-phase nonlinear parameter estimation for finned-tube coil evaporators

Author

S. Bueno, S., P. Dias, J., L. Seixlack, A., and B. Aparecido, J.

Abstract

A procedure for calculation of refrigerant mass flow rate is implemented in the distributed numerical model to simulate the flow in finned-tube coil dry-expansion evaporators, usually found in refrigeration and air-conditioning systems. Two-phase refrigerant flow inside the tubes is assumed to be one-dimensional, unsteady, and homogeneous. In the model the effects of refrigerant pressure drop and the moisture condensation from the air flowing over the external surface of the tubes are considered. The results obtained are the distributions of refrigerant velocity, temperature and void fraction, tube-wall temperature, air temperature, and absolute humidity. The finite volume method is used to discretize the governing equations. Additionally, given the operation conditions and the geometric parameters, the model allows the calculation of the refrigerant mass flow rate. The value of mass flow rate is computed using the process of parameter estimation with the minimization method of Levenberg-Marquardt minimization. In order to validate the developed model, the obtained results using HFC-134a as a refrigerant are compared with available data from the literature.

Published
2006
Full Text
View/download PDF

181. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.

Author

Delgallo, W. D., Rodrigues, J. R. P., Bueno, S. P., Viero, R. M., and Soares, C. T.

Subjects
*SMOOTH muscle, *BREAST cancer patients, *GENE expression, *ESTROGEN, *EPITHELIAL cells, *IMMUNOHISTOCHEMISTRY
Abstract

W. D. Delgallo, J. R. P. Rodrigues, S. P. Bueno, R. M. Viero and C. T. Soares Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma Objective: Gene expression studies have revealed several molecular subtypes of breast carcinoma with distinct clinical and biological behaviours. DNA microarray studies correlated with immunohistochemical profiling of breast carcinomas using cytokeratin (CK) markers, Her2/neu, oestrogen receptor (ER), and basal myoepithelial cell markers have identified five breast tumour subtypes: (i) luminal A (ER+; Her2/neu−), (ii) luminal B (ER+; Her2/neu+), (iii) Her2 overexpression (ER−; Her2/neu+), (iv) basal-like (ER−; Her2/neu−, CK5/6 and 14+), and (v) negative for all markers. Luminal carcinomas express cytokeratins in a luminal pattern (CK8/18), and the basal-like type expresses CK5/6 and CK14 or basal epithelial cell markers. CK5/6, CK8/18, and smooth muscle actin (SMA) expression were assessed in cell blocks and compared with expression in surgical specimens. Methods: Sixty-two cases of breast carcinoma diagnosed by fine needle aspiration cytology with cell blocks and available surgical specimens were included. Cell blocks containing at least 10 high-power fields each with at least 10 tumour cells and surgical specimens were immunostained for CK5/6, CK8/18 and SMA. Results: Percentage sensitivity, specificity, positive predictive value, negative predictive value and accuracy were, respectively, 77, 100, 100, 92 and 94 for CK5/6; 98, 66, 96, 80 and 95 for CK8/18; and 92, 96, 85, 98 and 95 for SMA. Conclusion: The identification of CK5/6, CK8/18 and SMA by immunohistochemistry in cell blocks can be a reliable method that yields results close to those obtained in surgical specimens, and can contribute to the classification of breast carcinomas with luminal and basal expression patterns, providing helpful information in the choice of treatment and in the evaluation of prognostic and predictive factors. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

182. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding.

Author

Danés, A. Farriols, Cuenca, L. Gallur, Bueno, S. Rodríguez, Mendarte Barrenechea, L., and Ronsano, J. Bruno Montoro

Subjects
*FIBRINOGEN polymorphisms, *FIBRINOGEN, *BLOOD coagulation factors, *HEMORRHAGE, *BLOOD plasma, *PATIENTS
Abstract

Background and Objectives Fibrinogen deficiency is a cause for massive haemorrhage whose management in emergency situations is the subject of debate. Plasma-derived fibrinogen concentrates are indicated for reversing the haemorrhagic diathesis found in congenital and acquired deficiencies. Materials and Methods We report on the results of an observational study that evaluated the effects of fibrinogen concentrates in patients suffering from various forms of acquired severe hypofibrinogenaemia with life-threatening consumptive thrombo-haemorrhagic disorders (surgery, trauma and digestive haemorrhage), or underlying disease states that limit fibrinogen synthesis (hepatic dysfunction, haematological malignancies). Results Sixty-nine patients were identified and included, in whom most of the processes (62%) corresponded to consumptive hypofibrinogenaemia. After a median dose of 4 g, a mean absolute increase of 1·09 g/l in plasma fibrinogen was measured and coagulation parameters were significantly improved ( P < 0·001). Mortality rates of 32·3% and 44·2% were reported after 24 h and 72 h, respectively. Conclusion We conclude that the administration of fibrinogen concentrates in unresponsive, life-threatening haemorrhage with acquired hypofibrinogenaemia improves laboratory measures of coagulation, and may also be life saving. Although observational in nature, our data indicate a direct relationship between plasma fibrinogen levels and survival in acquired fibrinogen deficiency. Further studies are warranted to ascertain a clear relationship between fibrinogen levels and survival. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

183. VP12.11: Fetal hydronephrosis and a atypical genital tract malformation.

Author

Amarante, Y. Pascoal Domingues, Negrao, J.D., de Paula, C.F., Morgado, N. Lourenco, Bueno, S. Paiva, Ferreira, J. Almeida, Sircili, M. Palma, and Barreto, E.Q.

Subjects
*GENITALIA, *HYDRONEPHROSIS, *HUMAN abnormalities, *AMNIOTIC liquid, *CONGENITAL disorders, *CYSTIC kidney disease
Abstract

The postnatal ultrasound findings were bilateral hydronephrosis and hiperechogenic parenchymal texture of the kidneys, normal bladder and abdominal hipoechogenic cyst. There is a strong association between malformations of the urinary system and the genital tract. On 31 week's gestation the amniotic fluid has become normal (AFI =15.0 cm), but the kidneys findings were the same. [Extracted from the article]

Published
2021
Full Text
View/download PDF

184. Gene expression profile study in CFTR mutated bronchial cell lines.

Author

Gambardella, S., Biancolella, M., D'Apice, M., Amati, F., Sangiuolo, F., Farcomeni, A., Chillemi, G., Bueno, S., Desideri, A., and Novelli, G.

Subjects
*GENE expression, *CELL lines, *CYSTIC fibrosis, *GENETIC mutation, *OBSTRUCTIVE lung diseases, *PHENOTYPES
Abstract

Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis conductance transmembrane regulator (CFTR). Symptoms are pancreatic insufficiency, chronic obstructive lung disease, liver disease, chronic sinusitis and infertility in male patients. The phenotypic variability may be explained only in part by the more than 1200 CFTR mutations, which are grouped into six different classes, according to their effect on the protein ranging from a severe (no synthesis or blocked processing) to mild mutation (altered conductance or reduced synthesis). However, it is now accepted that other genes (CF modifiers) influence the phenotypic spectrum of the disease. In order to identify CF modifier genes, we built a low-density home-made oligoarray containing 144 genes selected according to biochemical criteria and evaluated their expression in two CF bronchial epithelial cell lines (CuFi1 F508del/F508del; CuFi3 F508del/R553X). If we consider both cell lines, 38 genes (26.3%) show an altered expression pattern with a threshold >±1.5. Of these 38 genes, 12 are altered in CuFi1, and 26 in CuFi3. Some of these genes share the same expression pattern in both cell lines, while others have a different behaviour. These results were validated by a QRT-PCR assay ( R 2 CuFi1=0.81 and R 2 CuFi3=0.91). These data could suggest that the presence of a class I allele (R553X) determines a more profound alteration of gene expression pattern than the presence of a class II allele (F508del). The identification of the genes altered by a specific CF mutation could lead to the development of a pharmacological approach specific for different CFTR genotypes. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

185. A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway

Author

Sartelli, M., Kluger, Y., Ansaloni, L., Carlet, J., Brink, A., Hardcastle, T. C., Khanna, A., Chicom-Mefire, A., Rodríguez-Baño, J., Nathwani, D., Mendelson, M., Watkins, R. R., Pulcini, C., Beović, B., May, A. K., Itani, K. M. F., Mazuski, J. E., Fry, D. E., Coccolini, F., Rasxa, K., Montravers, P., Eckmann, C., Abbo, L. M., Abubakar, S., Abu-Zidan, F. M., Adesunkanmi, A. K., Al-Hasan, M. N., Althani, A. A., Ticas, J. E. A., Ansari, S., Ansumana, R., Da Silva, A. R. A. , Augustin, G. , Bala, M. , Balogh, Z. J. , Baraket, O. , Bassetti, M. , Bellanova, G. , Beltran, M. A. , Ben-Ishay, O. , Boermeester, M. A. , Brecher, S. M. , Bueno, J. , Cainzos, M. A. , Cairns, K. , Camacho-Ortiz, A. , Ceresoli, M. , Chandy, S. J. , Cherry-Bukowiec, J. R. , Cirocchi, R. , Colak, E. , Corcione, A. , Cornely, O. A. , Cortese, F. , Cui, Y. , Curcio, D. , Damaskos, D. , Dasx, K. , Delibegovic, S. , Demetrashvili, Z. be, De Simone, B. bf, De Souza, H. P. bg, De Waele, J. bh, Dhingra, S. bi, Diaz, J. J. bj, Di Carlo, I. bk, Di Marzo, F. bl, DI TOMASO, SAVERIO, S. , Dogjani, A. , Dorj, G. , Dortet, L. , Duane, T. M. , Dupont, H. , Egiev, V. N. , Eid, H. O. , Elmangory, El-Sayed Marei, H. , Enani, M. A. , Escandón-Vargas, K. , Faro, M. P. , J.r., Ferrada, P., Foghetti, D., Foianini, E., Fraga, G. P., Frattima, S., Gandhi, C., Gattuso, G., Giamarellou, E., Ghnnam, W., Gkiokas, G., Girardis, M., Goff, D. A., Gomes, C. A., Gomi, H., Gronerth, R. I. G., Guirao, X., Guzman-Blanco, M., Haque, M., Hecker, A., Hell, M., Herzog, T., Hicks, L., Kafka-Ritsch, R., Kao, L. S., Kanj, S. S., Kaplan, L. J., Kapoor, G., Karamarkovic, A., Kashuk, J., Kenig, J., Khamis, F., Khokha, V., Kiguba, R., Kirkpatrick, A. W., Kørner, H., Koike, K., Kok, K. Y. Y., Kon, K., Kong, V., Inaba, K., Ioannidis, O., Isik, A., Iskandar, K., Labbate, M., Labricciosa, F. M., Lagrou, K., Lagunes, L., Latifi, R., Lasithiotakis, K., Laxminarayan, R., Lee, J. G., Leone, M., Leppäniemi, A., Li, Y., Liang, S. Y., Liau, K. -.H., Litvin, A., Loho, T., Lowman, W., Machain, G. Mf, Maier, R. V., Manzano-Nunez, R., Marinis, A., Marmorale, C., Martin-Loeches, I., Marwah, S., Maseda, E., McFarlane, M., BEZERRA DE MELO PEREIRA NUNES, CINTIA, R. , Melotti, R. , Memish, Z. , Mertz, D. , Mesina, C. , Menichetti, F. , Mishra, S. K. , Montori, G. , Moore, E. E. , Moore, F. A. , Naidoo, NAPOLITANO, NELLO, L. , Negoi, I. , Nicolau, D. P. , Nikolopoulos, I. , Nord, C. E. , Ofori-Asenso, R. , Olaoye, I. , Omari, A. H. , Ordoñez, C. A. , Ouadii, M. , Ouedraogo, A. , Pagani, L. , Paiva, J. A. , Parreira, J. G. , Pata, F. fm, Pereira, J., Pereira, N. R., Petrosillo, N., Picetti, E., Pintar, T., Ponce-De-Leon, A., Popovski, Z., Poulakou, G., Preller, J., Guerrero, A. P., Pupelis, G., Quiodettis, M., Rawson, T. M., Reichert, M., Reinhart, K., Rems, M., Rello, J., Rizoli, S., ROBERTS, HENRI JOHAN EDUARD, Rubio-Perez, I., Ruppé, E., Sakakushev, B., Sall, I., Kafil, H. S. j, Sanders, J., Sato, N., Sawyer, R. G., T. , Scibé, R. , Scudeller, L. , Lohse, H. S. , Sganga, G. , Shafiq, N. , Shah, J. N. , Spigaglia, P. , Suroowan, S. , Tsioutis, C. , Sifri, C. D. , Siribumrungwong, B. , Sugrue, M. , Talving, P. , Tan, B. K. , Tarasconi, A. , Tascini, C. , Tilsed, J. , Timsit, J. -.F. , Tumbarello, M. , Trung, N. T. , Ulrych, J. , Uranues, S. , Velmahos, G. , Vereczkei, A. G. , Viale, P. , Estape, J. V. , Viscoli, C. , Wagenlehner, F. , Wright, B. J. , Xiao, Y. , Yuan, K. -.C. , Zachariah, S. K. , Zahar, J. R. , Mergulhão, P. , Catena, Réanimation Médico-Chirurgicale, Groupe Hospitalier Paris Saint-Joseph, University Hospital Virgen Macarena, Internal Medicine Department, Universidad de Sevilla, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Service d'anesthésie - réanimation chirurgicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Klinik I für Innere Medizin und Zentrum für Klinische Studien (ZKS) 01KN0706, Universitätsklinikum Köln (Uniklinik Köln), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CHU Amiens-Picardie, Paracelsus Medizinische Privatuniversität = Paracelsus Medical University (PMU), Université Catholique de Louvain = Catholic University of Louvain (UCL), Center for Disease Dynamics, Economics & Policy (CDDEP), Unité de Recherche sur les Maladies Infectieuses Tropicales Emergentes (URMITE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Hartford Hospital, Department of Laboratory Medicine, Karolinska Institutet [Stockholm], Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Instituto Nacional de Matemática Pura e Aplicada (IMPA), Instituto Nacional de matematica pura e aplicada, 4th Department of Internal Medicine, ATTIKON University General Hospital, Department of Anesthesiology and Intensive Care, Friedrich-Schiller-Universität = Friedrich Schiller University Jena [Jena, Germany], Critical Care Department, Joan XXIII University Hospital, Departmet of Infectious, Parasitic and Immune-Mediated Disease, Istituto Superiore di Sanita [Rome], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Section of Infectious Diseases, S.Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna (UNIBO), Infectious Diseases, University of Genoa (UNIGE), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Groupe Hospitalier Paris Saint-Joseph (hpsj), Universidad de Sevilla / University of Sevilla, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Istituto Superiore di Sanità (ISS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli studi di Genova = University of Genoa (UniGe), Sartelli, Massimo, Kluger, Yoram, Ansaloni, Luca, Carlet, Jean, Dorj, Gereltuya, Catena, Fausto, [Sartelli, Massimo] Macerata Hosp, Dept Surg, Macerata, Italy, [Scibe, Rodolfo] Macerata Hosp, Dept Surg, Macerata, Italy, [Kluger, Yoram] Rambam Hlth Care Campus, Dept Gen Surg, Div Surg, Haifa, Israel, [Ben-Ishay, Ofir] Rambam Hlth Care Campus, Dept Gen Surg, Div Surg, Haifa, Israel, [Ansaloni, Luca] Papa Giovanni XXIII Hosp, Gen Surg Dept, Bergamo, Italy, [Coccolini, Federico] Papa Giovanni XXIII Hosp, Gen Surg Dept, Bergamo, Italy, [Ceresoli, Marco] Papa Giovanni XXIII Hosp, Gen Surg Dept, Bergamo, Italy, [Montori, Giulia] Papa Giovanni XXIII Hosp, Gen Surg Dept, Bergamo, Italy, [Carlet, Jean] World Alliance Antibiot Resistance, Paris, France, [Brink, Adrian] Milpark Hosp, Ampath Natl Lab Serv, Dept Clin Microbiol, Johannesburg, South Africa, [Brink, Adrian] Univ Cape Town, Dept Med, Div Infect Dis & HIV Med, Cape Town, South Africa, [Hardcastle, Timothy C.] Inkosi Albert Luthuli Cent Hosp, Trauma Serv, Durban, South Africa, [Hardcastle, Timothy C.] Nelson R Mandela Sch Clin Med, Dept Surg, Durban, South Africa, [Khanna, Ashish] Ctr Crit Care, Anaesthesiol Inst, Cleveland, OH USA, [Khanna, Ashish] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA, [Chicom-Mefire, Alain] Univ Buea, Dept Surg & Obstet Gynaecol, Buea, Cameroon, [Foianini, Esteban] Univ Buea, Dept Surg & Obstet Gynaecol, Buea, Cameroon, [Rodriguez-Bano, Jesus] Hosp Univ Virgen Macarena & Virge del Rocio IbiS, Unidad Clin Interctr Enfermedades Infecciosas Mic, Seville, Spain, [Rodriguez-Bano, Jesus] Univ Seville, Dept Med, Seville, Spain, [Nathwani, Dilip] Ninewells Hosp & Med Sch, Dundee, Scotland, [Mendelson, Marc] Univ Cape Town, Groote Schuur Hosp, Dept Med, Div Infect Dis & HIV Med, Cape Town, South Africa, [Watkins, Richard R.] Cleveland Clin Akron Gen, Div Infect Dis, Akron, OH USA, [Watkins, Richard R.] Northeast Ohio Med Univ, Rootstown, OH USA, [Pulcini, Celine] Lorraine Univ, EA APEMAC 4360, Nancy, France, [Pulcini, Celine] Nancy Univ Hosp, Infect Dis Dept, Nancy, France, [Beovic, Bojana] Univ Med Ctr Ljubljana, Ljubljana, Slovenia, [Beovic, Bojana] Univ Ljubljana, Fac Med, Ljubljana, Slovenia, [May, Addison K.] Vanderbilt Univ, Med Ctr, Div Trauma & Surg Crit Care, Nashville, TN USA, [Itani, Kamal M. F.] Boston Univ, Dept Surg, VA Boston Hlth Care Syst, Boston, MA 02215 USA, [Itani, Kamal M. F.] Harvard Med Sch, Boston, MA USA, [Mazuski, John E.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA, [Fry, Donald E.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA, [Fry, Donald E.] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA, [Rasa, Kemal] Anadolu Med Ctr, Dept Surg, Kocaali, Turkey, [Montravers, Philippe] Bichat Claude Bernard Univ Hosp, Paris Diderot Sorbonne Cite Univ, Anesthesiol & Crit Care Med, HUPNSV, Paris, France, [Eckmann, Christian] Hannover Med Sch, Acad Hosp, Dept Gen Visceral & Thorac Surg, Peine, Germany, [Abbo, Lilian M.] Univ Miami, Miller Sch Med, Jackson Hlth Syst, Div Infect Dis, Miami, FL 33136 USA, [Abbo, Lilian M.] Bayero Univ, Dept Nursing Sci, Kano, Nigeria, [Abubakar, Salisu] UAE Univ, Coll Med & Hlth Sci, Dept Surg, Al Ain, U Arab Emirates, [Abu-Zidan, Fikri M.] Obafemi Awolowo Univ, Coll Hlth Sci, Dept Surg, Ife, Nigeria, [Al-Hasan, Majdi N.] Univ South Carolina, Sch Med, Dept Med, Div Infect Dis, Columbia, SC USA, [Althani, Asma A.] Qatar Univ, Biomed Res Ctr, Doha, Qatar, [Marei, Hany El-Sayed] Qatar Univ, Biomed Res Ctr, Doha, Qatar, [Ticas, Jorge Eduardo Alvarenga] Hosp Nacl Ros, Emergency Unit, San Salvador, El Salvador, [Ansari, Shamshul] Oita Univ, Dept Environm & Prevent Med, Fac Med, Oita, Japan, [Ansari, Shamshul] Chitwan Med Coll, Dept Microbiol, Bharatpur, Nepal, [Ansumana, Rashid] Univ Liverpool, Liverpool Sch Trop Med, Ctr Neglected Trop Dis, Bo, Sierra Leone, [Ansumana, Rashid] Njala Univ, Mercy Hosp, Res Lab, Bo, Sierra Leone, [Araujo da Silva, Andre Ricardo] Prontobaby Hosp Crianca, Infect Control Comm, Rio De Janeiro, Brazil, [Augustin, Goran] Univ Hosp Ctr, Dept Surg, Zagreb, Croatia, [Bala, Miklosh] Hadassah Hebrew Univ Med Ctr, Trauma & Acute Care Surg Unit, Jerusalem, Israel, [Balogh, Zsolt J.] John Hunter Hosp, Dept Traumatol, Newcastle, NSW, Australia, [Balogh, Zsolt J.] Univ Newcastle, Newcastle, NSW, Australia, [Baraket, Oussema] Bizerte Hosp, Dept Surg, Bizerte, Tunisia, [Bassett, Matteo] Santa Maria Misericordia Univ Hosp, Infect Dis Div, Udine, Italy, [Bellanova, Giovanni] SS Annunziata Hosp, Dept Surg, Taranto, Italy, [Beltran, Marcelo A.] Hosp San Juan Dios, Dept Gen Surg, La Serena, Chile, [Biffl, Walter L.] Queens Med Ctr, Acute Care Surg, Honolulu, HI USA, [Boermeester, Marja A.] Acad Med Ctr, Dept Surg, Amsterdam, Netherlands, [Brecher, Stephen M.] Boston Univ, Sch Med, VA Boston HealthCare Syst, Dept Pathol & Lab Med, Boston, MA 02118 USA, [Brecher, Stephen M.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA, [Bueno, Juan] Fdn Ctr Invest Bioprospecc & Biotecnol Biodivers, Barranquilla, Colombia, [Cainzos, Miguel A.] Hosp Clin Univ, Dept Surg, Santiago De Compostela, Spain, [Cairns, Kelly] Alfred Hlth, Pharm Dept, Melbourne, Vic, Australia, [Camacho-Ortiz, Adrian] Hosp Univ Dr Jose Eleuterio Gonzalez, Hosp Epidemiol & Infect Dis, Monterrey, Mexico, [Chandy, Sujith J.] Christian Med Coll & Hosp, Dept Pharmacol & Clin Pharmacol, Vellore, Tamil Nadu, India, [Cherry-Bukowiec, Jill R.] Univ Michigan, Dept Surg, Div Acute Care Surg, Ann Arbor, MI 48109 USA, [Cirocchi, Roberto] Univ Perugia, Dept Gen & Oncol Surg, Terni, Italy, [Colak, Elif] Hlth Sci Univ, Samsun Training & Res Hosp, Dept Gen Surg, Samsun, Turkey, [Corcione, Antonio] AORN Colli Vincenzo Monaldi Hosp, Anesthesia & Intens Care Unit, Naples, Italy, [Cornely, Oliver A.] Univ Cologne, German Ctr Infect Res DZIF, Dept Internal Med 1, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany, [Cortese, Francesco] San Filippo Neris Hosp, Emergency Surg Unit, Rome, Italy, [Cui, Yunfeng] Tianjin Med Univ, Tianjin Nankai Hosp, Dept Surg, Nankai Clin Sch Med, Tianjin, Peoples R China, [Curcio, Daniel] Buenos Aires Univ, Infectol Inst SRL, Buenos Aires, DF, Argentina, [Damaskos, Dimitris] Royal Infirm Edinburgh NHS Trust, Dept Surg, Edinburgh, Midlothian, Scotland, [Das, Koray] Ankara Numune Training & Res Hosp, Dept Surg, Adana, Turkey, [Delibegovic, Samir] Univ Clin Ctr Tuzla, Dept Surg, Tuzla, Bosnia & Herceg, [Deme-Trashvili, Zaza] Kipshidze Cent Univ Hosp, Dept Gen Surg, Tbilisi, Georgia, [De Simone, Belinda] Cannes Hosp, Dept Digest Surg, Cannes, France, [de Souza, Hamilton Petry] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Sch Med, Dept Surg, Porto Alegre, RS, Brazil, [De Waele, Jan] Ghent Univ Hosp, Dept Crit Care Med, Ghent, Belgium, [Dhingra, Sameer] Univ West Indies, Eric Williams Med Sci Complex, Sch Pharm, Fac Med Sci, Uriah Butler Highway, Champ Fleurs, Trinidad Tobago, [Diaz, Jose J.] Univ Maryland, R Adams Cowley Shock Trauma Ctr, Div Acute Care Surg, Program Trauma, Baltimore, MD 21201 USA, [Di Carlo, Isidoro] Univ Catania, Cannizzaro Hosp, Dept Surg Sci, Catania, Italy, [Di Marzo, Francesco] Versilia Hosp, Gen Surg, Usl Nordovest, Tuscany, Italy, [Di Saverio, Salomone] Maggiore Hosp, Dept Surg, Bologna, Italy, [Dogjani, Agron] Univ Hosp Trauma, Dept Surg, Tirana, Albania, [Dorj, Gereltuya] Mongolian Natl Univ Med Sci, Sch Pharm, Ulaanbaatar, Mongolia, [Dortet, Laurent] Paris Sud Univ, Bicetre Hosp, Dept Microbiol, La Kremlin Bicetre, France, [Duane, Therese M.] John Peter Smith Hlth Network, Dept Surg, Ft Worth, TX USA, [Dupont, Herve] Univ Picardie Jules Verne, CHU Amiens Picardie, Dept Anesthesie Reanimat, Amiens, France, [Dupont, Herve] Univ Picardie Jules Verne, INSERM, U1088, Amiens, France, [Egiev, Valery N.] Pirogov Russian Natl Res Med Univ, Dept Surg, Moscow, Russia, [Eid, Hani O.] Al Ain Hosp, Mediclin Middle East, Dept Emergency Med, Al Ain, U Arab Emirates, [Elmangory, Mutasim] Fed Minist Hlth, Sudan Natl Publ Hlth Lab, Khartoum, Sudan, [Enani, Mushira Abdulaziz] King Fahad Med City, Div Infect Dis, Dept Med, Riyadh, Saudi Arabia, [Escandon-Vargas, Kevin] Univ Valle, Escuela Med, Fac Salud, Cali, Colombia, [Faro Junior, Mario P.] ABC Med Sch, Dept Gen Surg Trauma, Santo Andre, SP, Brazil, [Faro Junior, Mario P.] ABC Med Sch, Emergency Surg Div, Santo Andre, SP, Brazil, [Ferrada, Paula] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA, [Foghetti, Domitilla] Pesaro Hosp, Dept Surg, Pesaro, Italy, Clin Foianini, Dept Surg, Santa Cruz, Bolivia, [Fraga, Gustavo P.] Univ Campinas Unicamp, Sch Med Sci, Dept Surg, Div Trauma Surg, Campinas, SP, Brazil, [Frattima, Sabrina] Ist Clin San Rocco Franciacorta, Brescia, Italy, [Gandhi, Chinmay] Bharati Vidyapeeth Deemed Univ Med Coll & Hosp, Dept Surg, Sangli, Maharashtra, India, [Gattuso, Gianni] C Poma Hosp, Infect Dis Dept, Mantua, Italy, [Giamarellou, Eleni] Hygeia Gen Hosp, Dept Internal Med 6, Athens, Greece, [Ghnnam, Wagih] Mansoura Univ, Mansoura Fac Med, Dept Gen Surg, Mansoura, Egypt, [Gkiokas, George] Natl & Kapodistrian Univ Athens, Aretaieion Univ Hosp, Dept Surg 2, Athens, Greece, [Girardis, Massimo] Modena Univ Hosp, Intens Care Unit, Modena, Italy, [Goff, Debbie A.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA, [Gomes, Carlos Augusto] Hosp Univ Terezinha Jesus, Dept Surg, Fac Ciencias Med & Saude Juiz de Fora, Juiz De Fora, Brazil, [Gomi, Harumi] Univ Tsukuba, Mito Kyodo Gen Hosp, Ctr Global Hlth, Mito, Ibaraki, Japan, [Guerra Gronerth, Rosio Isabel] Peruvian Navy Med Ctr, Lima, Peru, [Guirao, Xavier] Parc Tauli Univ Hosp, Dept Gen Surg, Unit Endocrine Head & Neck Surg, Sabadell, Spain, [Guirao, Xavier] Parc Tauli Univ Hosp, Dept Gen Surg, Unit Surg Infect Support, Sabadell, Spain, [Guzman-Blanco, Manuel] Hosp Privado Ctr Med Caracas, Caracas, Venezuela, [Guzman-Blanco, Manuel] Hosp Vargas Caracas, Caracas, Venezuela, [Haque, Mainul] Univ Pertahanan Nasional Malaysia, Natl Def Univ Malaysia, Unit Pharmacol, Fac Med & Def Hlth, Kuala Lumpur, Malaysia, [Reichert, Martin] Univ Pertahanan Nasional Malaysia, Natl Def Univ Malaysia, Unit Pharmacol, Fac Med & Def Hlth, Kuala Lumpur, Malaysia, [Hecker, Andreas] Univ Hosp Giessen, Dept Gen & Thorac Surg, Giessen, Germany, [Hell, Markus] Paracelsus Med Univ, Acad Teaching Lab, Clin Microbiol & Infect Control, MEDILAB Dr Mustafa Dr Richter OG, Salzburg, Austria, [Herzog, Torsten] Ruhr Univ Bochum, St Josef Hosp, Dept Surg, Bochum, Germany, [Hicks, Lauri] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA, [Kafka-Ritsch, Reinhold] Innsbruck Med Univ, Dept Visceral Transplant & Thorac Surg, Innsbruck, Austria, [Kao, Lillian S.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA, [Kanj, Souha S.] Amer Univ Beirut, Dept Internal Med, Div Infect Dis, Beirut, Lebanon, [Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, Philadelphia VA Med Ctr, Dept Surg, Philadelphia, PA 19104 USA, [Kapoor, Garima] Gandhi Med Coll, Dept Microbiol, Bhopal, India, [Karamarkovic, Aleksandar] Univ Belgrade, Clin Emergency Surg, Med Fac, Belgrade, Serbia, [Kashuk, Jeffry] Tel Aviv Univ, Dept Surg, Assia Med Grp, Sackler Sch Med, Tel Aviv, Israel, [Kenig, Jakub] Jagiellonian Univ, Med Coll, Dept Gen Surg 3, Krakow, Poland, [Khamis, Faryal] Royal Hosp, Dept Internal Med, Muscat, Oman, [Khokha, Vladimir] City Hosp, Dept Emergency Surg, Mozyr, BELARUS, [Kiguba, Ronald] Makerere Univ, Dept Pharmacol & Therapeut, Coll Hlth Sci, Kampala, Uganda, [Kirkpatrick, Andrew W.] Foothills Med Ctr, Gen Acute Care Abdominal Wall Reconstruct & Traum, Calgary, AB, Canada, [Korner, Hartwig] Stavanger Univ Hosp, Dept Gastrointestinal Surg, Stavanger, Norway, [Koike, Kaoru] Kyoto Univ, Grad Sch Med, Dept Primary Care & Emergency Med, Kyoto, Japan, [Kok, Kenneth Y. Y.] Brunei Canc Ctr, Dept Surg, Jerudong Pk, Jerudong, Brunei, [Kon, Kateryna] Kharkiv Natl Med Univ, Dept Microbiol Virol & Immunol, Kharkov, Ukraine, [Kong, Victor] Edendale Hosp, Dept Surg, Pietermaritzburg, South Africa, [Inaba, Kenji] Univ Southern Calif, Los Angeles Cty & Univ So Cali fornia Med Ctr, Div Acute Care Surg & Surg Crit Care, Dept Surg, Los Angeles, CA USA, [Ioannidis, Orestis] Aristotle Univ Thessaloniki, Gen Hosp G Papanikolaou, Surg Dept 4, Med Sch, Thessaloniki, Greece, [Isik, Arda] Erzincan Univ, Dept Gen Surg, Fac Med, Erzincan, Turkey, [Iskandar, Katia] Lebanese Int Univ, Dept Pharm, Beirut, Lebanon, [Labbate, Maurizio] Univ Technol Sydney, Sch Life Sci, Sydney, NSW, Australia, [Labbate, Maurizio] Univ Technol Sydney, Inst I3, Sydney, NSW, Australia, [Labricciosa, Francesco M.] UNIVPM, Dept Biomed Sci & Publ Hlth, Unit Hyg Prevent Med & Publ Hlth, Ancona, Italy, [Lagrou, Katrien] Univ Hosp Leuven, Clin Dept Lab Med, Leuven, Belgium, [Lagrou, Katrien] Katholieke Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium, [Lagunes, Leonel] Hosp Cent Dr Ignacio Morones Prieto, San Luis Potosi, Mexico, [Latifi, Rifat] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ USA, [Lasithiotakis, Kostas] York Teaching Hosp NHS Fdn Trust, Dept Surg, York, N Yorkshire, England, [Laxminarayan, Ramanan] Ctr Dis Dynam Econ & Policy, Washington, DC USA, [Lee, Jae Gil] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea, [Leone, Marc] Aix Marseille Univ, Hop Nord, AP HM, Dept Anaesthesiol & Crit Care, Marseille, France, [Leppaniemi, Ari] Univ Hosp Meilahti, Abdominal Ctr, Helsinki, Finland, [Li, Yousheng] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Surg, Shanghai, Peoples R China, [Liang, Stephen Y.] Washington Univ, Sch Med, Div Infect Dis, Div Emergency Med, St Louis, MO USA, [Liau, Kui-Hin] Natl Univ Singapore, Mt Elizabeth Novena Hosp, Singapore & Yong Loo Lin Sch Med, Dept Surg,Liau KH Consulting, Singapore, Singapore, [Litvin, Andrey] Immanuel Kant Balt Fed Univ, Surg Disciplines, Reg Clin Hosp, Kaliningrad, Russia, [Loho, Tonny] Univ Indonesia, Cipto Mangunkusumo Gen Hosp, Dept Clin Pathol, Div Infect Dis,Fac Med, Jakarta, Indonesia, [Lowman, Warren] Univ Witwatersrand, Sch Pathol, Vermaak Partners Pathcare Pathologists, Clin Microbiol & Infect Dis,Fac Hlth Sci, Johannesburg, South Africa, [Lowman, Warren] Wits Donald Gordon Med Ctr, Johannesburg, South Africa, [Machain, Gustavo M.] Univ Nacl Asuncion, Dept Surg, Asuncion, Paraguay, [Segovia Lohse, Helmut] Univ Nacl Asuncion, Dept Surg, Asuncion, Paraguay, [Maier, Ronald V.] Univ Washington, Dept Surg, Seattle, WA 98195 USA, [Manzano-Nunez, Ramiro] Fdn Valle Lili, Clin Res Ctr, Cali, Colombia, [Marinis, Athanasios] Tzane Gen Hosp, Dept Surg 1, Piraeus, Greece, [Marmorale, Cristina] Univ Politecn Marche, Dept Surg, Ancona, Italy, [Martin-Loeches, Ignacio] St James Univ Hosp, Trin Ctr Hlth Sci, Dept Clin Med, Wellcome Trust HRB Clin Res,MICRO, Dublin, Ireland, [Marwah, Sanjay] Postgrad Inst Med Sci, Dept Surg, Rohtak, Haryana, India, [Maseda, Emilio] Hosp Univ La Paz Madrid, Serv Anestesia & Reanimac, Madrid, Spain, [McFarlane, Michael] Univ Hosp West Indies, Dept Surg Radiol, Kingston, Jamaica, [de Melo, Renato Bessa] Ctr Hosp Sao Joao, Gen Surg Dept, Porto, Portugal, [Melotti, Maria Rita] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Anesthesiol & Intens Care, Bologna, Italy, [Memish, Ziad] Minist Hlth, Prince Mohamed Bin Abdulaziz Hosp, Dept Med, Infect Dis Div, Riyadh, Saudi Arabia, [Mertz, Dominik] McMaster Univ, Dept Med, Hamilton, ON, Canada, [Mertz, Dominik] McMaster Univ, Dept Clin Epidemiol & Biostat, Dept Pathol & Mol Med, Hamilton, ON, Canada, [Mesina, Cristian] Emergency Hosp Craiova, Surg Clin 2, Craiova, Romania, [Menichetti, Francesco] Univ Hosp Pisa, Infect Dis Unit, Pisa, Italy, [Mishra, Shyam Kumar] Tribhuvan Univ, Teaching Hosp, Inst Med, Dept Microbiol, Kathmandu, Nepal, [Moore, Ernest E.] Univ Colorado, Denver Hlth Med Ctr, Dept Surg, Denver, CO 80202 USA, [Moore, Frederick A.] Univ Florida, Coll Med, Dept Surg, Div Acute Care Surg, Gainesville, FL USA, [Moore, Frederick A.] Univ Florida, Coll Med, Ctr Sepsis & Crit Illness Res, Gainesville, FL USA, [Naidoo, Noel] Univ KwaZulu Natal, Dept Surg, Durban, South Africa, [Napolitano, Lena] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA, [Negoi, Ionut] Emergency Hosp Bucharest, Dept Surg, Bucharest, Romania, [Nicolau, David P.] Ctr Anti Infect Res & Dev, Hartford, CT USA, [Nikolopoulos, Ioannis] Lewisham & Greenwich NHS Trust, Dept Gen Surg, London, England, [Nord, Carl Erik] Karolinska Univ, Huddinge Hosp, Dept Lab Med, Div Clin Microbiol, Stockholm, Sweden, [Ofori-Asenso, Richard] Hlth Policy Consult, Res Unit, Weija, Accra, Ghana, [Olaoye, Iyiade] Univ Ilorin, Teaching Hosp, Dept Surg, Ilorin, Nigeria, [Omari, Abdelkarim H.] King Abdullah Univ Hosp, Dept Surg, Irbid, Jordan, [Ordonez, Carlos A.] Univ Valle, Fdn Valle Lili, Dept Surg & Crit Care, Cali, Colombia, [Ouadii, Mouaqit] Sidi Mohamed Benabdellah Univ, Hassan Univ Hosp 2, Dept Surg, Med Sch Fez, Fes, Morocco, [Ouedraogo, Abdoul-Salam] CHU Souro Sanou, Bacteriol & Virol Dept, Bobo Dioulasso, Burkina Faso, [Pagani, Leonardo] Bolzano Cent Hosp, Infect Dis Unit, Bolzano, Italy, [Paiva, Jose Artur] Univ Porto, Ctr Hosp Sao Joao, Intens Care Med Dept, Porto, Portugal, [Mergulhao, Paulo] Univ Porto, Ctr Hosp Sao Joao, Intens Care Med Dept, Porto, Portugal, [Parreira, Jose Gustavo] Santa Casa Sao Paulo Sch Med Sci, Dept Surg, Sao Paulo, Brazil, [Pata, Francesco] St Antonio Abate Hosp, Dept Surg, Gallarate, Italy, [Pereira, Jorge] Ctr Hosp Tondela Viseu, Surg Unit 1, Viseu, Portugal, [Pereira, Nuno R.] Sao Joao Hosp Ctr, Ctr Hosp Epidemiol, Unit Prevent & Infect Control, Porto, Portugal, [Petrosillo, Nicola] INMI Lazzaro Spallanzani IRCCS, Natl Inst Infect Dis, Rome, Italy, [Picetti, Edoardo] Univ Parma, Azienda Osped, Dept Anesthesia & Intens Care, Parma, Italy, [Pintar, Tadeja] UMC Ljubljana, Dept Surg, Ljubljana, Slovenia, [Ponce-de-Leon, Alfredo] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Lab Clin Microbiol, Mexico City, DF, Mexico, [Popovski, Zagorka] Hamilton Hlth Sci, Hamilton, ON, Canada, [Popovski, Zagorka] London Hlth Sci, London, ON, Canada, [Poulakou, Garyphallia] Attikon Univ Gen Hosp, Med Sch, Natl & Kapodistrian Univ Athens, Dept Internal Med 4, Athens, Greece, [Poulakou, Garyphallia] Attikon Univ Gen Hosp, Med Sch, Natl & Kapodistrian Univ Athens, Infect Dis Unit, Athens, Greece, [Preller, Jacobus] Univ Hosp NHS Fdn Trust, John Farman Intens Care Unit, Cambridge, England, [Guerrero, Adrian Puello] Univ Autonoma Santo Domingo, Inst Nacl Canc Rosa Tavares INCART, Santo Domingo, Dominican Rep, [Pupelis, Guntars] Riga East Univ Hosp Gailezers, Dept Gen & Emergency Surg, Riga, Latvia, [Quiodettis, Martha] Hosp Santo Tomas, Dept Trauma, Panama City, Panama, [Rawson, Timothy M.] Natl Inst Hlth Res, Imperial Coll London, Hlth Protect Res Unit Healthcare Associated Infec, Hammersmith Campus, London, England, [Reinhart, Konrad] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Thuringen, Germany, [Rems, Miran] Jesenice Gen Hosp, Dept Gen Surg, Jesenice, Slovenia, [Rello, Jordi] VHIR, Dept Clin Res & Innovat Pneumonia & Sepsis, Barcelona, Spain, [Rizoli, Sandro] Univ Toronto, St Michaels Hosp, Trauma & Acute Care Serv, Toronto, ON, Canada, [Roberts, Jason] Univ Queensland, Fac Med, Brisbane, Qld, Australia, [Rubio-Perez, Ines] La Paz Univ Hosp, Gen Surg Dept, Colorectal Surg Unit, Madrid, Spain, [Ruppc, Etienne] Bichat Claude Bernard Univ Hosp, Paris Diderot Sorbonne Univ, Serv Bacteriol, HUPNSV, Paris, France, [Sakakushev, Boris] Univ Hosp St George, Med Univ, Gen Surg Dept, Plovdiv, Bulgaria, [Sall, Ibrahima] Mil Teaching Hosp, Gen Surg Dept, Dakar, Senegal, [Kafil, Hossein Samadi] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran, [Sanders, James] JPS Hlth Network, Ft Worth, TX USA, [Sato, Norio] Ehime Univ, Grad Sch Med, Dept Aeromed Serv Emergency & Trauma Care, Matsuyama, Ehime, Japan, [Sawyer, Robert G.] Western Michigan Univ, Sch Med, Dept Surg, Kalamazoo, MI 49008 USA, [Scalea, Thomas] Univ Maryland, Sch Med, Dept Trauma Surg, Baltimore, MD 21201 USA, [Scudeller, Luigia] IRCCS Policlin San Matteo Fdn, Clin Epidemiol Unit, Pavia, Italy, [Sganga, Gabriele] Univ Cattolica Sacro Cuore, Policlin A Gemelli, Dept Surg, Rome, Italy, [Shafiq, Nusrat] Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh, India, [Shah, Jay N.] Patan Acad Hlth Sci, Dept Surg Patan Hosp, Kathmandu, Nepal, [Spigaglia, Patrizia] Ist Super Sanita, Dept Infect Dis, Rome, Italy, [Suroowan, Shanoo] Univ Mauritius, Dept Hlth Sci, Fac Sci, Reduit, Mauritius, [Tsioutis, Constantinos] European Univ Cyprus, Sch Med, Nicosia, Cyprus, [Sifri, Costi D.] Univ Virginia Hlth Syst, Off Hosp Epidemiol Infect Prevent & Control, Charlottesville, VA USA, [Siribumrungwong, Boonying] Thammasat Univ Hosp, Thammasat Univ, Dept Surg, Fac Med, Pathum Thani, Thailand, [Sugrue, Michael] Letterkenny Hosp, Gen Surg Dept, Letterkenny, Ireland, [Talving, Peep] North Estonia Med Ctr, Dept Surg, Tallinn, Estonia, [Tan, Boun Kim] Ctr Hosp St Joseph St Luc, Intens Care Unit, Lyon, France, [Tarasconi, Antonio] Parma Maggiore Hosp, Dept Emergency Surg, Parma, Italy, [Catena, Fausto] Parma Maggiore Hosp, Dept Emergency Surg, Parma, Italy, [Tascini, Carlo] Cotugno Hosp, Azienda Osped Colli, Div Infect Dis 1, Naples, Italy, [Tilsed, Jonathan] Hull & East Yorkshire Hosp NHS Trust, Surg Hlth Care Grp, Kingston Upon Hull, N Humberside, England, [Timsit, Jean-Francois] Hop Xavier Bichat, PHP Med & Infect Dis ICU, Paris, France, [Tumbarello, Mario] Catholic Univ, Inst Infect Dis, Rome, Italy, [Ngo Tat Trung] Tran Hung Dao Hosp, Dept Mol Biol, Hanoi, Vietnam, [Ulrych, Jan] Charles Univ Prague, Fac Med 1, Dept Surg 1, Prague, Czech Republic, [Ulrych, Jan] Gen Univ Hosp Prague, Prague, Czech Republic, [Uranues, Selman] Med Univ Graz, Dept Surg, Graz, Austria, [Velmahos, George] Massachusetts Gen Hosp, Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA, [Vereczkei, Andras G.] Med Sch Univ Pecs, Dept Surg, Pecs, Hungary, [Viale, Pierluigi] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Infect Dis Unit, Bologna, Italy, [Vila Estape, Jordi] Univ Barcelona, ISGlobal Hosp Clin, Inst Salud Global, Barcelona, Spain, [Viscoli, Claudio] Univ Genoa DISSAL, Osped Policlin San Martino IRCCS Oncol, Infect Dis Unit, Genoa, Italy, [Wagenlehner, Florian] Univ Giessen, Dept Urol Pediat Urol & Androl, Med Fac Justus Liebig, Giessen, Germany, [Wright, Brian J.] SUNY Stony Brook, Sch Med, Dept Emergency Med & Neurosurg, Stony Brook, NY 11794 USA, [Xiao, Yonghong] Zhejiang Univ, Affilliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Hangzhou, Zhejiang, Peoples R China, [Yuan, Kuo-Ching] Chang Gung Mem Hosp, Trauma & Emergency Surg Dept, Taoyuan, Taiwan, [Zachariah, Sanoop K.] MOSC Med Coll Kolenchery, Dept Surg, Cochin, Kerala, India, [Zahar, Jean Ralph] Angers Univ, CHU Angers, Infect Control Unit, Angers, France, COMBE, Isabelle, Sartelli, M, Kluger, Y, Ansaloni, L, Carlet, J, Brink, A, Hardcastle, T, Khanna, A, Chicom-Mefire, A, Rodriguez-Bano, J, Nathwani, D, Mendelson, M, Watkins, R, Pulcini, C, Beovic, B, May, A, Itani, K, Mazuski, J, Fry, D, Coccolini, F, Rasxa, K, Montravers, P, Eckmann, C, Abbo, L, Abubakar, S, Abu-Zidan, F, Adesunkanmi, A, Al-Hasan, M, Althani, A, Ticas, J, Ansari, S, Ansumana, R, Da Silva, A, Augustin, G, Bala, M, Balogh, Z, Baraket, O, Bassetti, M, Bellanova, G, Beltran, M, Ben-Ishay, O, Biffl, W, Boermeester, M, Brecher, S, Bueno, J, Cainzos, M, Cairns, K, Camacho-Ortiz, A, Ceresoli, M, Chandy, S, Cherry-Bukowiec, J, Cirocchi, R, Colak, E, Corcione, A, Cornely, O, Cortese, F, Cui, Y, Curcio, D, Damaskos, D, Dasx, K, Delibegovic, S, Demetrashvili, Z, De Simone, B, De Souza, H, De Waele, J, Dhingra, S, Diaz, J, Di Carlo, I, Di Marzo, F, Di Saverio, S, Dogjani, A, Dorj, G, Dortet, L, Duane, T, Dupont, H, Egiev, V, Eid, H, Elmangory, M, El-Sayed Marei, H, Enani, M, Escandon-Vargas, K, Faro, M, Ferrada, P, Foghetti, D, Foianini, E, Fraga, G, Frattima, S, Gandhi, C, Gattuso, G, Giamarellou, E, Ghnnam, W, Gkiokas, G, Girardis, M, Goff, D, Gomes, C, Gomi, H, Gronerth, R, Guirao, X, Guzman-Blanco, M, Haque, M, Hecker, A, Hell, M, Herzog, T, Hicks, L, Kafka-Ritsch, R, Kao, L, Kanj, S, Kaplan, L, Kapoor, G, Karamarkovic, A, Kashuk, J, Kenig, J, Khamis, F, Khokha, V, Kiguba, R, Kirkpatrick, A, Korner, H, Koike, K, Kok, K, Kon, K, Kong, V, Inaba, K, Ioannidis, O, Isik, A, Iskandar, K, Labbate, M, Labricciosa, F, Lagrou, K, Lagunes, L, Latifi, R, Lasithiotakis, K, Laxminarayan, R, Lee, J, Leone, M, Leppaniemi, A, Li, Y, Liang, S, Liau, K, Litvin, A, Loho, T, Lowman, W, Machain, G, Maier, R, Manzano-Nunez, R, Marinis, A, Marmorale, C, Martin-Loeches, I, Marwah, S, Maseda, E, Mcfarlane, M, De Melo, R, Melotti, M, Memish, Z, Mertz, D, Mesina, C, Menichetti, F, Mishra, S, Montori, G, Moore, E, Moore, F, Naidoo, N, Napolitano, L, Negoi, I, Nicolau, D, Nikolopoulos, I, Nord, C, Ofori-Asenso, R, Olaoye, I, Omari, A, Ordonez, C, Ouadii, M, Ouedraogo, A, Pagani, L, Paiva, J, Parreira, J, Pata, F, Pereira, J, Pereira, N, Petrosillo, N, Picetti, E, Pintar, T, Ponce-De-Leon, A, Popovski, Z, Poulakou, G, Preller, J, Guerrero, A, Pupelis, G, Quiodettis, M, Rawson, T, Reichert, M, Reinhart, K, Rems, M, Rello, J, Rizoli, S, Roberts, J, Rubio-Perez, I, Ruppe, E, Sakakushev, B, Sall, I, Kafil, H, Sanders, J, Sato, N, Sawyer, R, Scalea, T, Scibe, R, Scudeller, L, Lohse, H, Sganga, G, Shafiq, N, Shah, J, Spigaglia, P, Suroowan, S, Tsioutis, C, Sifri, C, Siribumrungwong, B, Sugrue, M, Talving, P, Tan, B, Tarasconi, A, Tascini, C, Tilsed, J, Timsit, J, Tumbarello, M, Trung, N, Ulrych, J, Uranues, S, Velmahos, G, Vereczkei, A, Viale, P, Estape, J, Viscoli, C, Wagenlehner, F, Wright, B, Xiao, Y, Yuan, K, Zachariah, S, Zahar, J, Mergulhao, P, Catena, F, Sartelli, M., Kluger, Y., Ansaloni, L., Carlet, J., Brink, A., Hardcastle, T. C., Khanna, A., Chicom-Mefire, A., Rodríguez-Baño, J., Nathwani, D., Mendelson, M., Watkins, R. R., Pulcini, C., Beović, B., May, A. K., Itani, K. M. F., Mazuski, J. E., Fry, D. E., Coccolini, F., Rasxa, K., Montravers, P., Eckmann, C., Abbo, L. M., Abubakar, S., Abu-Zidan, F. M., Adesunkanmi, A. K., Al-Hasan, M. N., Althani, A. A., Ticas, J. E. A., Ansari, S., Ansumana, R., Da, Silva, Augustin, A. R. A., Bala, G., Balogh, M., Baraket, Z. J., Bassetti, O., Bellanova, M., Beltran, G., Ben-Ishay, M. A., Boermeester, O., Brecher, M. A., Bueno, S. M., Cainzos, J., Cairns, M. A., Camacho-Ortiz, K., Ceresoli, A., Chandy, M., Cherry-Bukowiec, S. J., Cirocchi, J. R., Colak, R., Corcione, E., Cornely, A., Cortese, O. A., Cui, F., Curcio, Y., Damaskos, D., Dasx, D., Delibegovic, K., Demetrashvili, S., Be, Z., Simone, De, Bf, B., De, Souza, Bg, H. P., De, Waele, Bh, J., Dhingra, Bi, S., Diaz, Bj, J. J., Carlo, Di, Bk, I., Di, Marzo, Bl, F., Saverio, Di, Dogjani, S., Dorj, A., Dortet, G., Duane, L., Dupont, T. M., Egiev, H., Eid, V. N., Elmangory, H. O., El-Sayed, Marei, Enani, H., Escandón-Vargas, M. A., Faro, K., M. P., J. r., Ferrada, P., Foghetti, D., Foianini, E., Fraga, G. P., Frattima, S., Gandhi, C., Gattuso, G., Giamarellou, E., Ghnnam, W., Gkiokas, G., M., Girardi, Goff, D. A., Gomes, C. A., Gomi, H., Gronerth, R. I. G., Guirao, X., Guzman-Blanco, M., Haque, M., Hecker, A., Hell, M., Herzog, T., Hicks, L., Kafka-Ritsch, R., Kao, L. S., Kanj, S. S., Kaplan, L. J., Kapoor, G., Karamarkovic, A., Kashuk, J., Kenig, J., Khamis, F., Khokha, V., Kiguba, R., Kirkpatrick, A. W., Kørner, H., Koike, K., Kok, K. Y. Y., Kon, K., Kong, V., Inaba, K., Ioannidis, O., Isik, A., Iskandar, K., Labbate, M., Labricciosa, F. M., Lagrou, K., Lagunes, L., Latifi, R., Lasithiotakis, K., Laxminarayan, R., Lee, J. G., Leone, M., Leppäniemi, A., Li, Y., Liang, S. Y., Liau, K. -. H., Litvin, A., Loho, T., Lowman, W., Machain, Mf, G., Maier, R. V., Manzano-Nunez, R., Marinis, A., Marmorale, C., Martin-Loeches, I., Marwah, S., Maseda, E., Mcfarlane, M., De, Melo, Melotti, R., Memish, R., Mertz, Z., Mesina, D., Menichetti, C., Mishra, F., Montori, S. K., Moore, G., Moore, E. E., Naidoo, F. A., Napolitano, N., Negoi, L., Nicolau, I., Nikolopoulos, D. P., Nord, I., Ofori-Asenso, C. E., Olaoye, R., Omari, I., Ordoñez, A. H., Ouadii, C. A., Ouedraogo, M., Pagani, A., Paiva, L., Parreira, J. A., Pata, J. G., F., Fm, Pereira, J., Pereira, N. R., Petrosillo, N., Picetti, E., Pintar, T., Ponce-De-Leon, A., Popovski, Z., Poulakou, G., Preller, J., Guerrero, A. P., Pupelis, G., Quiodettis, M., Rawson, T. M., Reichert, M., Reinhart, K., Rems, M., Rello, J., Rizoli, S., Roberts, J., Rubio-Perez, I., Ruppé, E., Sakakushev, B., Sall, I., Kafil, H. S. j, Sanders, J., Sato, N., Sawyer, R. G., Scibé, T., Scudeller, R., Lohse, L., Sganga, H. S., Shafiq, G., Shah, N., Spigaglia, J. N., Suroowan, P., Tsioutis, S., Sifri, C., Siribumrungwong, C. D., Sugrue, B., Talving, M., Tan, P., Tarasconi, B. K., Tascini, A., Tilsed, C., Timsit, J., Tumbarello, J. -. F., Trung, M., Ulrych, N. T., Uranues, J., Velmahos, S., Vereczkei, G., Viale, A. G., Estape, P., Viscoli, J. V., Wagenlehner, C., Wright, F., Xiao, B. J., Yuan, Y., Zachariah, K. -. C., Zahar, S. K., Mergulhão, J. R., and Catena, P.

Subjects
0301 basic medicine, antibiotic agent, antifungal agent antiinfective agent, Antifungal Agents, Drug Resistance, Declaration, Inappropriate Prescribing, 030230 surgery, Global Health, Antimicrobial Stewardship, Microbial, 0302 clinical medicine, Anti-Infective Agents, Health care, Global health, Antimicrobial stewardship, Antibiotic prophylaxis, Antibiotic stewardship, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Drug Resistance, Microbial, Public relations, Antimicrobial, Operative, Anti-Bacterial Agents, Antibiotic Prophylaxis, Humans, Surgical Procedures, Operative, Surgical Wound Infection, Surgery, Microbiology (medical), Infectious Diseases, 3. Good health, surgical infections, medicine.medical_specialty, 030106 microbiology, Guidelines, 03 medical and health sciences, Antibiotic resistance, medicine, Ventilator-associated pneumonia, Adults, Surgical Procedures, business.industry, Carbapenems, Therapy, business, hospitals, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; This declaration, signed by an interdisciplinary task force of 234 experts from 83 different countries with different backgrounds, highlights the threat posed by antimicrobial resistance and the need for appropriate use of antibiotic agents and antifungal agents in hospitals worldwide especially focusing on surgical infections. As such, it is our intent to raise awareness among healthcare workers and improve antimicrobial prescribing. To facilitate its dissemination, the declaration was translated in different languages.

Published
2017
Full Text
View/download PDF

186. Primary adrenal lymphoma: a case series study.

Author

Schreiber, C. S. O., Sakon, J. R., Simião, F. P. C., Tomarchio, M. P., Huayllas, M., Pereira, L. C. M. M., Stella, L. C., Santomauro Jr., A. C., Bueno, S. S. S., and Fraige, F. F.

Subjects
*LETTERS to the editor
Abstract

A letter to the editor that discusses several cases of patients with primary adrenal lymphoma (PAL) is presented.

Published
2008
Full Text
View/download PDF

187. Ordinal regression algorithms for the analysis of convective situations over Madrid-Barajas airport.

Author

Guijo-Rubio, D., Casanova-Mateo, C., Sanz-Justo, J., Gutiérrez, P.A., Cornejo-Bueno, S., Hervás, C., and Salcedo-Sanz, S.

Subjects
*CONVECTIVE clouds, *REGRESSION analysis, *ORDINAL numbers, *SUPPORT vector machines, *AIRPORTS
Abstract

In this paper we tackle a problem of convective situations analysis at Adolfo-Suarez Madrid-Barajas International Airport (Spain), based on Ordinal Regression algorithms. The diagnosis of convective clouds is key in a large airport like Barajas, since these meteorological events are associated with strong winds and local precipitation, which may affect air and land operations at the airport. In this work, we deal with a 12-h time horizon in the analysis of convective clouds, using as input variables data from a radiosonde station and also from numerical weather models. The information about the objective variable (convective clouds presence at the airport) has been obtained from the Madrid-Barajas METAR and SPECI aeronautical reports. We treat the problem as an ordinal regression task, where there exist a natural order among the classes. Moreover, the classification problem is highly imbalanced, since there are very few convective clouds events compared to clear days. Thus, a process of oversampling is applied to the database in order to obtain a better balance of the samples for this specific problem. An important number of ordinal regression methods are then tested in the experimental part of the work, showing that the best approach for this problem is the SVORIM algorithm, based on the Support Vector Machine strategy, but adapted for ordinal regression problems. The SVORIM algorithm shows a good accuracy in the case of thunderstorms and Cumulonimbus clouds, which represent a real hazard for the airport operations. • Convective situations at Madrid-Barajas airport are analyzed. • Ordinal Regression algorithms are considered. • The study is based on Radio-sonde station and reanalysis data. • Support Vector Regression for ordinal regression is the best tested approach. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

188. Transcriptomic investigation of meat tenderness in two Italian cattle breeds

Author

Cesare Ernesto Maria Gruber, Fabrizio Ferrè, Susana Bueno, Bianca Moioli, S. Failla, Alessio Valentini, Giovanni Chillemi, Silvia Bongiorni, Bongiorni, S, Gruber, C.E.M., Bueno, S., Chillemi, G., Ferrè, F., Failla, S., Moioli, B., and Valentini, A.

Subjects
0301 basic medicine, Gene isoform, Meat, Maremmana, Muscle Proteins, Single-nucleotide polymorphism, AMP-Activated Protein Kinases, Breeding, Biology, Chianina, Polymorphism, Single Nucleotide, meat quality, 03 medical and health sciences, Meat tenderness, Genetic, Gene expression, Genetics, Animals, Allele, Muscle, Skeletal, Promoter Regions, Genetic, Gene, Alleles, Sequence Analysis, RNA, High-Throughput Nucleotide Sequencing, General Medicine, PRKAG3 gene, biology.organism_classification, Alternative Splicing, 030104 developmental biology, MRNA Sequencing, Italy, skeletal muscle transcriptome, Cattle, Animal Science and Zoology, Transcriptome
Abstract

Our objectives for this study were to understand the biological basis of meat tenderness and to provide an overview of the gene expression profiles related to meat quality as a tool for selection. Through deep mRNA sequencing, we analyzed gene expression in muscle tissues of two Italian cattle breeds: Maremmana and Chianina. We uncovered several differentially expressed genes that encode for proteins belonging to a family of tripartite motif proteins, which are involved in growth, cell differentiation and apoptosis, such as TRIM45, or play an essential role in regulating skeletal muscle differentiation and the regeneration of adult skeletal muscle, such as TRIM32. Other differentially expressed genes (SCN2B, SLC9A7 and KCNK3) emphasize the involvement of potassium-sodium pumps in tender meat. By mapping splice junctions in RNA-Seq reads, we found significant differences in gene isoform expression levels. The PRKAG3 gene, which is involved in the regulation of energy metabolism, showed four isoforms that were differentially expressed. This distinct pattern of PRKAG3 gene expression could indicate impaired glycogen storage in skeletal muscle, and consequently, this gene very likely has a role in the tenderization process. Furthermore, with this deep RNA-sequencing, we captured a high number of expressed SNPs, for example, we found 1462 homozygous SNPs showing the alternative allele with a 100% frequency when comparing tender and tough meat. SNPs were then classified into categories by their position and also by their effect on gene coding (174 non-synonymous polymorphisms) based on the available UMD_3.1 annotations.

Published
2016

189. Skeletal muscle transcriptional profiles in two Italian beef breeds, Chianina and Maremmana, reveal breed specific variation

Author

Silvia Bongiorni, Susana Bueno, Alessio Valentini, S. Failla, Fabrizio Ferrè, Cesare Ernesto Maria Gruber, Bianca Moioli, Giovanni Chillemi, Bongiorni, S, Gruber, C E M, Chillemi, G, Bueno, S, Failla, S, Moioli, B, Ferrè, F, and Valentini, A

Subjects
Male, 0301 basic medicine, Maremmana, Energy metabolism, Single-nucleotide polymorphism, Breeding, Beef cattle, Polymorphism, Single Nucleotide, 03 medical and health sciences, Genetics, Skeletal Muscle Tissue, medicine, Animals, Chianiana, Muscle, Skeletal, Molecular Biology, Breed selection, biology, Gluconeogenesis, 0402 animal and dairy science, Skeletal muscle, 04 agricultural and veterinary sciences, General Medicine, biology.organism_classification, 040201 dairy & animal science, Breed, Red Meat, 030104 developmental biology, medicine.anatomical_structure, MRNA Sequencing, Italy, Evolutionary biology, Cattle, RNA-seq, Transcriptome, Glycolysis
Abstract

Chianina and Maremmana breeds play an important role in the Italian cattle meat market. The Chianina breed is an ancient breed principally raised for draught. Now this breed is the worldwide recognized producer of top quality beef, tasteful and tender, specifically the famous "Florentine steak". The Maremmana characterized by a massive skeletal structure, is a rustic cattle breed selected for adaptability to the marshy land of the Maremma region. We used a high throughput mRNA sequencing to analyze gene expression in muscle tissues of two Italian cattle breeds, Maremmana (MM) and Chianina (CN) with different selection history. We aim to examine the specific genetic contribution of each breed to meat production and quality, comparing the skeletal muscle tissue from Maremmana and Chianina. Most of the differentially expressed genes were grouped in the Glycolysis/Gluconeogenesis pathways. The rate and the extent of post-mortem energy metabolism have a critical effect on the conversion of muscle to meat. Furthermore, we aim at discovering the differences in nucleotide variation between the two breeds which might be attributable to the different history of selection/divergence. In this work we could emphasize the involvement of pathways of post-mortem energy metabolism. Moreover, we detected a collection of coding SNPs which could offer new genomic resources to improve phenotypic selection in livestock breeding program.

Published
2016

190. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors

Author

Alessandra Russo, Luca Lotito, Giovanni Capranico, Susana Bueno, Giovanni Chillemi, Maria Vittoria Fogli, Lotito L., Russo A., Bueno S., Chillemi G., Fogli M.V., and Capranico G.

Subjects
DNA Replication, Saccharomyces cerevisiae Proteins, Time Factors, Transcription, Genetic, Genes, Fungal, Cell, Down-Regulation, Antineoplastic Agents, Saccharomyces cerevisiae, Biology, Sensitivity and Specificity, chemistry.chemical_compound, Transcription (biology), medicine, Gene Regulatory Networks, heterocyclic compounds, Promoter Regions, Genetic, Transcription factor, Gene, neoplasms, Cell Proliferation, Pharmacology, Base Sequence, Cell growth, Topoisomerase, Cell Cycle, Molecular biology, Up-Regulation, DNA-Binding Proteins, medicine.anatomical_structure, DNA Topoisomerases, Type I, chemistry, Mutation, biology.protein, Camptothecin, DNA, Transcription Factors, medicine.drug
Abstract

Topoisomerase I (Top1) is the specific target of the anticancer drug camptothecin (CPT) that interferes with enzyme activity promoting Top1-mediated DNA breaks and inhibition of DNA and RNA synthesis. To define the specific transcriptional response to CPT, we have determined the CPT-altered transcription profiles in yeast by using a relatively low concentration of the drug. CPT could alter global expression profiles only if a catalytically active Top1p was expressed in the cell, demonstrating that drug interference with Top1 was the sole trigger of the response. A total of 95 genes showed a statistically-significant alterations. Gene Ontology term analyses suggested that the cell response was mainly to the inhibition of nucleic acid synthesis and cell cycle progression. Promoter sequence analyses of the 22 up-regulated genes and expression studies in gene-deleted strains showed that the transcription factors, Swi4p and Mbp1p, mediate at least partially the transcriptional response to CPT. The MBP1 gene deletion abrogates a transient cell growth delay caused by CPT whereas the SWI4 gene deletion increases yeast resistance to CPT. Thus, the findings show that yeast cells have a highly selective and sensitive transcriptional response to CPT depending on SWI4 and MBP1 genes suggesting a complex regulation of cell cycle progression by the two factors in the presence of CPT.

Published
2009

191. Global transcription regulation by DNA topoisomerase I in exponentially growing Saccharomyces cerevisiae cells: Activation of telomere-proximal genes by TOP1 deletion

Author

Duccio Cavalieri, Alessandra Russo, Luca Lotito, Susana Bueno, Giovanni Capranico, Giovanni Chillemi, Lotito L., Russo A., Chillemi G., Bueno S., Cavalieri D., and Capranico G.

Subjects
Transcription, Genetic, Saccharomyces cerevisiae, Mutant, Down-Regulation, Catalysis, Histones, Structural Biology, Transcription (biology), Gene Expression Regulation, Fungal, Transcriptional regulation, DNA, Fungal, Molecular Biology, Gene, Silent Information Regulator Proteins, Saccharomyces cerevisiae, Regulation of gene expression, biology, Acetylation, Telomere, biology.organism_classification, Molecular biology, Chromatin, Enzyme Activation, Histone, Glucose, DNA Topoisomerases, Type I, Mutation, biology.protein, Chromosomes, Fungal, Gene Deletion
Abstract

To establish the cellular functions of DNA topoisomerase I-B (Top1p) at a global level, we have determined the expression profiles and histone modification patterns affected by TOP1 gene deletion (ΔTOP1) in Saccharomyces cerevisiae. In exponentially growing cells, ΔTOP1 specifically increases transcription of telomere-proximal genes and decreases glucose utilization and energy production pathways. Immunoprecipitation data demonstrate that Top1p can bind to and is catalytically active at telomeric DNA repeats, and that both ΔTOP1 and an inactive Y727F Top1p mutant increase H4 histone acetylation at telomere-proximal regions. Interestingly, while the Y727F mutation has no influence on enzyme recruitment to chromatin sites, it has a marked effect on H4 K16 acetylation at subtelomeric regions. The Top1p mutation also increases H3 histone K4 dimethylation, which has been associated with gene transcription, at 3′ termini of subtelomeric genes. No major effect of ΔTOP1 or mutation was detected on Sir3p recruitment; however, ΔTOP1 has an effect on transcript levels of genes known to regulate telomeric silencing. Thus, the findings indicate that Top1p activity can favor both a repressed chromatin organization and a reduced gene expression level at telomere-proximal regions in yeast. As telomere-proximal regions are known to be enriched for stress-activated genes, our findings show that Top1p can optimize transcript levels for cell growth in exponentially growing cells under a synthetic medium with glucose.

Published
2008

192. Crecimiento fetal en el Hospital Universitario Ramón González Valencia

Author

Reinaldo Mora Restrepo, Abelardo Orostegui S., César Augusto Bueno S., and Enrique Arias I.

Subjects
Gynecology and obstetrics, RG1-991
Abstract

En 2.000 recién nacidos vivos, 1.023 del sexo femenino y 977 del masculino, se calcularon curvas de crecimiento fetal relacionando el peso, la talla, el perímetro cefálico y el índice pondoestatural con la edad gestacional. Para la elaboración de las curvas patrones se excluyeron los hijos de madres con alguna patología, los gemelares, los malformados, los hijos de fumadoras, de madres con amenorrea dudosa o que hubieran ingerido anticonceptivos en los tres meses anteriores a la última regla. Se realizaron medidas entre las semanas 36 y 42 de la gestación. La ganancia pondoestatural entre las semanas estudiadas fue uniformemente progresiva y por los estimativos máximo y mínimo podemos concluir que la población sobre la cual nuestro hospital tiene influencia fue muy homogénea en sus características. Se encontró un ligero predominio de los parámetros estudiados del sexo masculino sobre el sexo femenino. Por la revisión de estudios extranjeros encontramos diferencias grandes especialmente en la distribución de los pesos al nacimiento. No comparamos nuestros hallazgos con algún estudio institucional nacional por no haber hallado ninguna referencia.

Published
1986
Full Text
View/download PDF

193. Superficial musculoaponeurotic system interpositional graft after temporomandibular joint discectomy.

Author

Bueno S and Sanovich R

Subjects
Humans, Female, Adult, Male, Arthroplasty methods, Pain Measurement, Middle Aged, Treatment Outcome, Temporomandibular Joint Disorders surgery, Temporomandibular Joint Disc surgery, Diskectomy methods, Superficial Musculoaponeurotic System surgery, Superficial Musculoaponeurotic System transplantation
Abstract

Arthroplasty with discectomy is a proven treatment for internal derangement of the temporomandibular joint (TMJ), however there is no consensus on the type of interpositional graft that should be used after the disc is removed. While an ideal graft should be easy to obtain and provide an adequate buffer between the articular surfaces, the authors suggest that it should also minimize donor site morbidity. This Technical Note highlights the technique for harvesting and utilizing the superficial musculoaponeurotic system (SMAS) as an interpositional graft. Three patients were treated with a SMAS graft after TMJ arthroplasty with discectomy. The average pain score decreased from 9/10 preoperatively to 2/10 at 6 weeks postoperatively, while the average maximum incisal opening increased from 31 mm to 36.7 mm. Since these patients were concurrently treated with a facelift, they were asked about their esthetic outcome on a scale of 1-10, with 1 representing extremely dissatisfied and 10 representing extremely satisfied. The average esthetic rating at 6 weeks postoperatively was 9.3/10. The SMAS interpositional graft technique eliminates a second surgical site, improves function, reduces pain, and provides the opportunity for concurrent esthetic facial rejuvenation if desired., Competing Interests: Competing interests None., (Copyright © 2024 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

194. Lactobacillus rhamnosus modulates murine neonatal gut microbiota and inflammation caused by pathogenic Escherichia coli.

Author

Xuan H, Umar S, Zhong C, Yu W, Ahmed I, Wheatley JL, Sampath V, and Chavez-Bueno S

Subjects
Animals, Rats, Rats, Sprague-Dawley, Neonatal Sepsis microbiology, Neonatal Sepsis prevention & control, Disease Models, Animal, Apoptosis, Lacticaseibacillus rhamnosus physiology, Gastrointestinal Microbiome, Probiotics administration & dosage, Escherichia coli genetics, Escherichia coli pathogenicity, Animals, Newborn, Escherichia coli Infections microbiology, RNA, Ribosomal, 16S genetics, Inflammation microbiology
Abstract

Background: Pathogenic Escherichia coli strains produce neonatal septicemia after colonizing the neonatal gut. While the probiotic Lactobacillus rhamnosus GG (LGG) effectively reduces neonatal sepsis, LGG's effects on the neonatal intestinal microbiota alterations and inflammation triggered by E. coli are incompletely understood. We hypothesized that LGG significantly modulates the specific neonatal gut microbial populations changes and the inflammatory response elicited by the enteral introduction of septicemia-producing E. coli. To test this hypothesis, newborn rats were pretreated orally with LGG or placebo prior to infection with the neonatal E. coli septicemia clinical isolate SCB34. Amplicon 16S rRNA gene sequencing was performed on intestinal samples. Intestinal injury and expression of inflammatory mediators and apoptosis were determined., Results: Alpha diversity of gut microbiota was greater in SCB34-infected pups in comparison to sham-infected pups, these changes were not modified by LGG pretreatment. Beta diversity analyses also showed differences between SCB34-infected vs. uninfected pups. LGG pretreatment before SCB34 infection did not result in significant beta diversity changes compared to placebo. Moreover, individual genera and species abundance analyses by linear discriminant analysis effect size (LEfSe) showed significant changes in Gram-negative, Gram-positive, and anaerobic populations resulting from LGG pretreatment and SCB34 infection. LGG significantly suppressed the expression of inflammatory cytokines but did not attenuate SCB34-induced apoptosis or histologic injury., Conclusions: LGG modulates clinically significant microbiota features and inflammation triggered by pathogenic E. coli intestinal infection shortly after birth. This new knowledge can potentially be harnessed to design novel interventions against gut-derived neonatal sepsis., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

195. Are More Medically Complex Patients Who Undergo Complex Septorhinoplasty at an Increased Risk for Surgical Site Infection?

Author

Cannon S, Carr BR, Neal TW, Sarcos P, Bueno S, and Finn RA

Subjects
Humans, Male, Female, Retrospective Studies, Middle Aged, Adult, Risk Factors, Aged, Surgical Wound Infection etiology, Rhinoplasty, Antibiotic Prophylaxis, Nasal Septum surgery
Abstract

Background: Prophylactic antibiotics are routinely prescribed by surgeons for their patients who undergo septorhinoplasty. However, the literature to support this remains controversial, especially in complex cases, those that require grafts, revision cases, extended surgical time, and an American Society of Anesthesiologists (ASA) value greater than or equal to 3., Purpose: The study purpose was to evaluate for a potential association between increased anesthetic complexity and the risk for surgical site infection (SSI) following complex septorhinoplasty., Study Design, Setting, Sample: Retrospective cohort study of patients who underwent a complex septorhinoplasty between 2005 and 2022 at the Dallas Veterans Affairs Medical Center. Patients were excluded if they did receive a septorhinoplasty, did not follow up, or had insufficient records., Independent Variable: All patients were assigned an ASA value prior to surgery, with an ASA value of 3 serving as this study's independent variable., Main Outcome Variable: The main outcome variable of interest was the development of a postoperative SSI, defined as findings consistent with cellulitis, purulence, or fistula development necessitating antibiotic treatment., Covariates: The demographic covariates included patient age and sex. Clinical covariates included diabetes status, history of nasal trauma or surgery, and smoking status. The operative covariates were surgical duration, perioperative antibiotic, intraoperative complication, and type of cartilage graft used., Analyses: χ 2 Analysis and t-tests were used for calculations, with P values < .05 being considered significant., Results: A total of 182 patients were included in this study, 81 (45%) with an ASA ≤2 and 101 (55%) with an ASA of 3. A patient's age (P < .01), male sex (P < .01), and a diagnosis of diabetes (P < .01) were associated with an ASA value of 3. In total, there were 6 (3.3%) SSIs, with 2 (1%) occurring in those with an ASA of 3. An ASA value of 3 (P = .27, relative risk of .40) was not shown to be associated with an increased risk of SSI., Conclusion and Relevance: Our results suggest that an ASA of 3 is not significant with regard to postoperative infection in patients who undergo a complex nasal septorhinoplasty, and prophylactic postoperative antibiotics are not warranted., (Copyright © 2024 American Association of Oral and Maxillofacial Surgeons. All rights reserved.)

Published
2024
Full Text
View/download PDF

196. Bioelectrical impedance-derived phase angle (PhA) in people living with obesity: Role in sarcopenia and comorbidities.

Author

Carretero Gómez J, González Gónzalez P, Galeano Fernández TF, Córdoba Bueno S, Boyero Calvo N, Salgado Cardoso B, and Arévalo Lorido JC

Subjects
Humans, Female, Male, Middle Aged, Aged, Risk Factors, Cross-Sectional Studies, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic diagnosis, Heart Failure physiopathology, Heart Failure epidemiology, Heart Failure diagnosis, Predictive Value of Tests, Body Composition, Risk Assessment, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 physiopathology, Adiposity, Inflammation epidemiology, Inflammation physiopathology, Sarcopenia epidemiology, Sarcopenia physiopathology, Sarcopenia diagnosis, Electric Impedance, Obesity epidemiology, Obesity physiopathology, Obesity diagnosis, Comorbidity, Muscle, Skeletal physiopathology
Abstract

Background and Aim: Obesity is characterized by alterations in fat and muscle mass. Phase angle (PhA) is considered an index of muscle mass, and is related to comorbidities in SO. This work aimed to assess the relationship between PhA, muscle mass, inflammation, and comorbidities in obesity., Methods and Results: We included 198 outpatients with obesity (BMI≥30) divided into tertiles according to PhA distribution (<5°, 5°-6°, >7°). Body composition was analyzed using bioimpedance (Tanita MC-780P Multi-Frequency Segmental Body Composition Analyzer). Quantitative variables were compared using the Kruskal-Wallis test and qualitative variables using the chi-square test. A correspondence analysis was built to show the influence of qualitative variables on subjects in each tertile. Patients in the lowest tertile had the lowest skeletal muscle mass and appendicular skeletal muscle mass index (ASMI); the highest inflammatory index (albumin and derived neutrophil-to-lymphocyte ratio, Alb-dNLR); and the highest percentage of individuals with a history of type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and heart failure (HF). The correspondence analysis showed an association between the lowest tertile and presence of HF with preserved ejection fraction (HFpEF) and CKD. On the logistic regression model, ASMI (OR 0.9, 95%CI 0.85-0.95, p = 0.0004), Alb-dNLR (OR 1.04, 95%CI 1.04-16.4, p = 0.04) and HFpEF and T2DM were significantly associated with the lowest PhA., Conclusions: Identifying high-risk individuals living with obesity is a priority. These results show that lower PhA is related to inflammation, poorer skeletal muscle mass and consequently, their impact on obesity-related comorbidities and clinical outcomes., (Copyright © 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

197. Analyzing the Behavior Towards the Use of Interactive Digital Whiteboards for Educational Purposes: A Proposal Based on the Model of Goal-Directed Behavior and the Theory of Planned Behavior.

Author

Gallego MD, Bagozzi R, Bueno S, and Racero FJ

Abstract

Information and communication technologies have revolutionized the educational landscape, transforming teaching and learning processes across the globe, and this is the case for interactive digital whiteboards. In particular, this paper focuses on providing a research model to analyze the behavior towards the use of interactive digital whiteboards (IDWs) by teachers in the educational context, highlighting their impact on the intention to use IDWS. The proposed structural equation model is based on the model of goal-directed behavior and the theory of planned behavior, and it is formed by six constructs: (1) attitude, (2) subjective norms, (3) desire, (4) perceived behavioral control, (5) intentions, and (6) behavior. The methodology was adapted to two possible scenarios: (1) positive and (2) negative. The findings show that both theoretical frameworks offer a valid context to explain the motivations that drive the use of IDWs, although there are no significant differences between the two scenarios. Thus, the present article contributes to the existing body of knowledge and provides insights for educators, policymakers, and researchers to leverage the acceptance of IDWs in education. However, some limitations were identified, such as the absence of the point of view of students regarding the use of IDWs, among others.

Published
2024
Full Text
View/download PDF

198. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study.

Author

Mirallas O, Martin-Cullell B, Navarro V, Vega KS, Recuero-Borau J, Gómez-Puerto D, López-Valbuena D, Salva de Torres C, Andurell L, Pedrola A, Berché R, Palmas F, Ucha JM, Villacampa G, Rezqallah A, Sanz-Beltran J, Bach R, Bueno S, Viaplana C, Molina G, Hernando-Calvo A, Aguilar-Company J, Roca M, Muñoz-Couselo E, Martínez-Martí A, Alonso A, Eremiev S, Macarulla T, Oaknin A, Saura C, Élez E, Felip E, Peñuelas Á, Burgos R, Pardo PG, Garralda E, Tabernero J, Serradell S, Servitja S, Paez D, Dienstmann R, and Carles J

Abstract

Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best predict mortality in hospitalized patients receiving active systemic treatment. Our main goal was to develop a predictive model for 90-day mortality upon admission., Methods: Between 2020 and 2022, we prospectively collected data from three sites for cancer patients with hospitalizations. Those with metastatic disease receiving systemic therapy in the 6 months before unplanned admission were eligible to this study. The least absolute shrinkage and selection operator (LASSO) method was used to select the most relevant factors to predict 90-day mortality at admission. A multivariable logistic regression was fitted to create the PROgnostic Score for Hospitalized Cancer Patients (PROMISE) score. The score was developed in a single-center training cohort and externally validated., Findings: Of 1658 hospitalized patients, 1009 met eligibility criteria. Baseline demographics, patient and disease characteristics were similar across cohorts. Lung cancer was the most common tumor type in both cohorts. Factors associated with higher 90-day mortality included worse ECOG, stable/progressive disease, low levels of albumin, increased absolute neutrophil count, and high lactate dehydrogenase. The c-index after bootstrap correction was 0.79 (95% CI, 0.75-0.82) and 0.74 (95% CI, 0.68-0.80) in the training and validation cohorts, respectively. A web tool (https://promise.vhio.net/) was developed to facilitate the clinical deployment of the model., Interpretation: The PROMISE tool demonstrated high performance for identifying metastatic cancer patients who are alive 90 days after an unplanned hospitalization. This will facilitate healthcare providers with rational clinical decisions and care planning after discharge., Funding: Merck S.L.U., Spain., Competing Interests: OM reports writing aid from Merck and Roche, and travel aid from Almirall, Kyowa Kirin, and Recordati. JR reports payment or honoraria for lectures from Merck and LEO Pharma, and travel aid from Adamed and LEO Pharma. DG reports payment or honoraria for lectures from LEO Pharma. RB is currently employed by AstraZeneca. GV reports consulting fees from Reveal Genomics, and payment or honoraria for lectures from MSD, Pierre Fabre, Pfizer, and GSK. SB reports payment or honoraria for lectures from Pfizer, and travel aid from MSD. AH reports grants for research support from Gilead, and payment or honoraria for lectures at the TTCC and THNO congresses. MR reports payment or honoraria for lectures from ROVI. EM reports consulting fees from BMS, MSD, Novartis, Sanofi, Pierre Fabre, Regeneron, Inmunocore, and Roche, payment or honoraria for lectures from BMS, MSD, Novartis, Sanofi, Pierre Fabre, Regeneron, and Inmunocore, and travel aid from MSD and Novartis. AM reports consulting fees from AstraZeneca, BMS, Roche, and MSD, payment or honoraria from AstraZeneca, BMS, Roche, participation as a steering committee member for AstraZeneca, travel aid from AstraZeneca, BMS, and Roche, and participation on the advisory board for AstraZeneca, MSD, and BMS. TM reports grants from MSD, Novocure, QED Therapeutics, Roche, Sanofi-Aventis, Servier, Zymeworks, consulting fees from Ability Pharmaceuticals SL, Arcus Bioscience Inc., AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Incyte, Ipsen Bioscience Inc., payment or honoraria from Janssen, Lilly, Esteve, Daïchi, Biontech, Novartis, Jazz Pharmaceuticals, and travel aid from Servier, AstraZeneca, Sanofi, Incyte, Lilly, MSD, and Roche. AO reports consulting fees from AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Daiichi Sankyo, Debiopharm International, Eisai, Exelixis, F. Hoffmann-La Roche, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana Therapeutics, Myriad Genetics, Novocure, OncoXerna Therapeutics Inc., PharmaMar, Regeneron, Sattucklabs, Seagen/Pfizer, Sutro Biopharma, and Zentalis; travel aid from AstraZeneca, PharmaMar, and Roche, and participation on the advisory board for AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Daiichi Sankyo, Debiopharm International, Eisai, Exelixis, F. Hoffmann-La Roche, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana Therapeutics, Myriad Genetics, Novocure, OncoXerna Therapeutics Inc., PharmaMar, Regeneron, Sattucklabs, Seagen/Pfizer, Sutro Biopharma, and Zentalis. CS reports grants from AX'Consulting, AX's Consulting SARL, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Byondis BV, Daiichi Sankyo, Eisai, Exeter Pharma, F. Hoffmann-La Roche Ltd, Genentech, Grupo de Mama Alemán, Galaad, Glaxo, INDITEX, ISSECAM, Innoup, Grupo Internacional de Estudio del Cáncer de Mama (IBCSG), Liriomacrogénicos, MediTech, Consultoría de Estadísticas Médicas, Medseñor, Menarini, Merck Sharp & Dohme, Merus, Milenio, Instituto Holandés del Cáncer (NKI), Novartis, Pfizer, Philips, Pierre Fabre, Pintafarma, Puma, Queen Mary (University of London), Roche Farma, SACE Medhealth SL, Sanofi, Sanofi Aventis, Seagen, Genética de Seattle, Simon Kucher & Partners SL, Solti, Biofarmacéuticos Synthon, and Zymeworks, consulting fees from AstraZeneca, Daiichi Sankyo, Eisai Europe Ltd., Gilead, Novartis, Pharmalex, Pfizer Inc., Philips Health Works, Pierre Fabre, PintPharma, Puma Biotechnology Inc., Roche Farma SA, Seagen International, Solti, Synthon Biopharmaceuticals, and Zymeworks, payment or honoraria for lectures from AstraZeneca, Daiichi Sankyo, Eisai Europe Ltd., Gilead, Novartis, Pharmalex, Pfizer Inc., Philips Health Works, Pierre Fabre, PintPharma, Puma Biotechnology Inc., Roche Farma SA, Seagen International, Solti, Synthon Biopharmaceuticals, Zymeworks, Sociedade Portuguesa de Oncología, travel aid from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer Inc., Pierre Fabre, PintPharma, Roche Farma SA, Seagen International, Solti, participation on an advisory board for AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer Inc., Pierre Fabre, PintPharma, Roche Farma SA, Seagen, and research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd. EE reports consulting fees from Amgen, Bayer, Cure Teq, AG Hoffmann-La Roche, BMS, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics, RIN Institute, Sanofi, payment or honoraria for lectures from Amgen, Bayer, Cure Teq, AG Hoffmann-La Roche, BMS, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Sanofi, Seagen, Servier and Takeda, travel aid from Amgen, Bayer, Cure Teq, AG Hoffmann-La Roche, BMS, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Sanofi, Seagen, Servier and Takeda, and participation on Advisory Board for Amgen, Bayer, Cure Teq, AG Hoffmann-La Roche, BMS, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics, RIN Institute, Sanofi, Seagen, Servier and Takeda. EF reports consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Genmab, Gilead, GlaxoSmithKline, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Regeneron, Sanofi, Takeda, Turning Point, and Daiichi Sankyo; payment or honoraria for lectures from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, PeerVoice, Pfizer, Sanofi, Takeda, and Touch Oncology; payment for expert testimony from AstraZeneca, Janssen, and Roche; and is an independent member of the board for Grifols. EG reports grants from Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene, and Janssen; consulting fees from Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Thermo Fisher, MabDiscovery, Anaveon, F-Star Therapeutics, Hengrui, Sanofi, Incyte, Medscape, Pfizer, and Amgen; payment or honoraria for lectures from Merck Sharp & Dohme, Roche, Thermo Fisher, Novartis, and SeaGen; employment for NEXT Oncology; and serves as a principal investigator for Adaptimmune LLC, Affimed GmbH, Amgen SA, Anaveon AG, AstraZeneca AB, Bicycletx Ltd, BioInvent International AB, Biontech SE, Biontech Small Molecules GmbH, Boehringer Ingelheim International GmbH, Catalym GmbH, Cyclacel Biopharmaceuticals, Cytovation AS, Cytomx, F. Hoffmann-La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hifibio Therapeutics, Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Incyte Corporation, Incyte Europe Sàrl, Janssen-Cilag International NV, Janssen-Cilag SA, Laboratorios Servier SL, Medimmune LLC, Merck & Co., Inc., Merck KGaA, Novartis Farmacéutica S.A., Peptomyc, Pfizer Slu, Relay Therapeutics, Replimmune, Ribon Therapeutics, Ryvu Therapeutics SA, Seattle Genetics Inc., Sotio AS, Sqz Biotechnologies, Symphogen A/S, Taiho Pharma USA Inc., and T-Knife GmbH. JT reports consulting fees from Alentis Therapeutics, AstraZeneca, Aveo Oncology, Boehringer Ingelheim, Cardiff Oncology, CARSgen Therapeutics, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, hC Bioscience, Ikena Oncology, Immodulon Therapeutics, Inspirna Inc, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Takeda Oncology, and Tolremo Therapeutics; payment or honoraria from Medscape Education, PeerView Institute for Medical Education, and Physicians' Education Resource (PER); and stocks in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology, and 1TRIALSP. DP reports grants from Merck; consulting fees from Amgen, Ipsen, and Esteve; payment or honoraria for lectures from Amgen, Novartis, and BMS; and travel aid from Amgen, Merck, Roche, Lilly, Servier, Sanofi, and Ipsen. RD reports grants from Merck, Novartis, Daiichi-Sankyo, GlaxoSmithKline, and AstraZeneca; consulting fees from Roche, Foundation Medicine, and AstraZeneca; payment or honoraria for lectures from Roche, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, Lilly, AstraZeneca, Janssen, Takeda, Bristol-Myers Squibb, GlaxoSmithKline, and Gilead; and holds stocks in Trialing Health. JC reports consulting fees from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Ipsen, Johnson & Johnson, MSD Oncology, Novartis (AAA), Pfizer, Sanofi, payment or honoraria for lectures from Astellas Pharma, Bayer, Johnson & Johnson, Sanofi, and support for attending meetings from BMS, Ipsen, Roche, AstraZeneca, and Bayer. Disclosures have been attached in a separate document by each author. More detailed disclosures can be found in the ICMJE forms uploaded. All other authors declare no conflicts of interest., (© 2024 The Author(s).)

Published
2024
Full Text
View/download PDF

199. An Investigational Study on the Role of CYP2D6 , CYP3A4 and UGT s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers.

Author

Rodríguez-Lopez A, Ochoa D, Soria-Chacartegui P, Martín-Vilchez S, Navares-Gómez M, González-Iglesias E, Luquero-Bueno S, Román M, Mejía-Abril G, and Abad-Santos F

Abstract

Introduction: Fesoterodine is one of the most widely used antimuscarinic drugs to treat an overactive bladder. Fesoterodine is extensively hydrolyzed by esterases to 5-hydroxymethyl tolterodine (5-HMT), the major active metabolite. CYP2D6 and CYP3A4 mainly metabolize 5-HMT and are, therefore, the primary pharmacogenetic candidate biomarkers. Materials and Methods: This is a candidate gene study designed to investigate the effects of 120 polymorphisms in 33 genes (including the CYP, COMT, UGT, NAT2, and CES enzymes, ABC and SLC transporters, and 5-HT receptors) on fesoterodine pharmacokinetics and their safety in 39 healthy volunteers from three bioequivalence trials. Results: An association between 5-HMT exposure (dose/weight corrected area under the curve (AUC/DW) and dose/weight corrected maximum plasma concentration (C max /DW)), elimination (terminal half-life (T 1/2 ) and the total drug clearance adjusted for bioavailability (Cl/F)), and CYP2D6 activity was observed. Poor/intermediate metabolizers (PMs/IMs) had higher 5-HMT AUC/DW (1.5-fold) and C max /DW (1.4-fold) values than the normal metabolizers (NMs); in addition, the normal metabolizers (NMs) had higher 5-HMT AUC/DW (1.7-fold) and C max /DW (1.3-fold) values than the ultrarapid metabolizers (UMs). Lower 5-HMT exposure and higher T 1/2 were observed for the CYP3A4 IMs compared to the NMs, contrary to our expectations. Conclusions: CYP2D6 might have a more important role than CYP3A4 in fesoterodine pharmacokinetics, and its phenotype might be a better predictor of variation in its pharmacokinetics. An association was observed between different genetic variants of different genes of the UGT family and AUC, C max , and CL/F of 5-HMT, which should be confirmed in other studies.

Published
2024
Full Text
View/download PDF

200. Rev1Δwzm vaccine candidate is safe in young and adult sheep and protects against Brucella ovis infection in rams.

Author

Mena-Bueno S, Garrido V, Romero F, Zabalza-Baranguá A, and Grilló MJ

Subjects
Animals, Sheep, Female, Male, Antibodies, Bacterial blood, Antibodies, Bacterial immunology, Vaccination veterinary, Vaccination methods, Brucella melitensis immunology, Brucella melitensis genetics, Brucellosis prevention & control, Brucellosis veterinary, Brucellosis immunology, Sheep Diseases prevention & control, Sheep Diseases immunology, Brucella Vaccine immunology, Brucella Vaccine administration & dosage, Brucella ovis immunology, Brucella ovis genetics
Abstract

Small ruminants affected by brucellosis, caused mainly by Brucella melitensis and B. ovis, suffer reproductive disorders, leading to significant economic losses worldwide. Vaccination is an essential tool to prevent the disease in ovine and caprine livestock, but the only vaccine recommended to date is B. melitensis Rev1, which in sheep is only safe for use in lambs aged 3-4 months. This restriction poses considerable practical challenges for the implementation of Rev1 in countries with endemic brucellosis and/or limited resources, where there is a need for mass vaccination with a safe vaccine to control the disease in both animals and humans. We recently developed a B. melitensis strain Rev1Δwzm showing superior vaccine properties in mice and safety in pregnant ewes. Here, we report that Rev1Δwzm (i) is safe in young and adult sheep, both male and female; (ii) induces a transient serological response in the Rose Bengal test in ≤50 % of sheep, confirmed to some extent by the complement fixation test, and a stronger, more persistent anti- rough-LPS response; and (iii) protects rams against a B. ovis challenge 25 weeks after vaccination. To resolve the problem of serological interference, the use of green fluorescent protein tagging strategy allowed us to identify vaccinated sheep with only a single inoculation. These results, together with the previously reported safety in pregnant ewes, position Rev1Δwzm as a firm vaccine candidate and a promising alternative to Rev1. Further experiments are warranted to assess its efficacy against B. melitensis in pregnant ewes., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rev1Δwzm is protected under a CSIC-UPNA patent in PCT countries, but neither of these public institutions have participated in the studies or have any conflict of interests with this publication., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results